Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
JP4100623B2 - Composition of herbal extract with nicotine and dioxin detoxification - Google Patents
[go: Go Back, main page]

JP4100623B2 - Composition of herbal extract with nicotine and dioxin detoxification - Google Patents

Composition of herbal extract with nicotine and dioxin detoxification Download PDF

Info

Publication number
JP4100623B2
JP4100623B2 JP2003336533A JP2003336533A JP4100623B2 JP 4100623 B2 JP4100623 B2 JP 4100623B2 JP 2003336533 A JP2003336533 A JP 2003336533A JP 2003336533 A JP2003336533 A JP 2003336533A JP 4100623 B2 JP4100623 B2 JP 4100623B2
Authority
JP
Japan
Prior art keywords
extract
nicotine
tcdd
group
herbal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2003336533A
Other languages
Japanese (ja)
Other versions
JP2005082587A (en
Inventor
キム,ヒュン−サック
パク,キ−ムーン
ホワン,ジン−クック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2005082587A publication Critical patent/JP2005082587A/en
Application granted granted Critical
Publication of JP4100623B2 publication Critical patent/JP4100623B2/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/48Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105Plant extracts, their artificial duplicates or their derivatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/28Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A61K36/288Taraxacum (dandelion)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/35Caprifoliaceae (Honeysuckle family)
    • A61K36/355Lonicera (honeysuckle)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/78Saururaceae (Lizard's-tail family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00Food ingredients
    • A23V2250/20Natural extracts
    • A23V2250/21Plant extracts
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Botany (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)

Description

本発明は、ニコチン及びダイオキシンのような現代の代表的な毒性物質の体内解毒作用を持つ生薬抽出物で構成される組成物に関する。   The present invention relates to a composition composed of a herbal extract having an in vivo detoxifying action of typical modern toxic substances such as nicotine and dioxin.

人体に関連した有害物質としては、外部から摂取される薬物及び食品由来の毒性物質、微生物、汚染された空気、水などや体内の代謝過程で発生する過酸化物及びフリーラジカル(free radical)、腸内の有害微生物が生成する毒素などがある。そして、外部環境と体内の相互作用で発生する有害物質としては、マイクロ波及び超音波、電磁波、騒音、紫外線、放射線などにより人体の固有振動数が干渉を受けて神経系の異常を招き、内分泌系に異常を引き起こし、細胞の突然変異誘発及び有害物質の生成で新陳代謝に影響を与えることが知られている(Kwon, Y. T. Environmental contamination and human exposure by dioxin-like compounds. The Research Institute of Engineering Technology. 15:851-867(1998))。このように現代の環境が各種有害物質により広範囲に汚染されるに伴って、人体の免疫力が低下し、健康な生を享受することができる機会が少なくなっているが、これらのうちしばしば接することができる最も代表的な有害物質として、喫煙関連物質及び廃棄物焼却時に発生する環境ホルモンを挙げることができる。   Toxic substances related to the human body include externally ingested drugs and food-derived toxic substances, microorganisms, polluted air, water, peroxides and free radicals generated during metabolic processes in the body, Toxins produced by harmful microorganisms in the intestines. As harmful substances generated by the interaction between the external environment and the body, the natural frequency of the human body is interfered by microwaves and ultrasonic waves, electromagnetic waves, noise, ultraviolet rays, radiation, etc., leading to abnormalities in the nervous system and endocrine secretion. It is known to cause abnormalities in the system and affect metabolism by mutagenesis of cells and generation of harmful substances (Kwon, YT Environmental contamination and human exposure by dioxin-like compounds. The Research Institute of Engineering Technology. 15: 851-867 (1998)). In this way, as the modern environment is extensively polluted with various harmful substances, the immunity of the human body declines and the chances of enjoying healthy life are decreasing, but we often come in contact with them. The most representative harmful substances that can be mentioned are smoking-related substances and environmental hormones generated during waste incineration.

タバコの代表的な有害物質であるニコチン(nicotine)は、肺ガンを誘発する物質であるニトロソアミン-4-(メチルニトロソアミノ)-1-(3-ピリジル)-1-ブタノン{nitrosamine-4(methylnitrosamino)-1-(3-pyridyl)-1-butanone(NNK)}の前駆体であって、強力な環境毒素である。ニコチンの急性毒性の症状には、瞳孔縮小、角膜混濁、嘔吐、呼吸困難、唾液や呼吸器官での分泌物増加、心臓搏動数減少などを誘発し、慢性中毒の場合、体内に蓄積され各種循環系疾患を誘発できる(Brunneman, K. D., Prokopezyk, B., Djordjevic, M. V. and Hoffmann, D. Formation and analysis of tobacco-specific N-nitrosamines. J. Natl. Cancer Inst. 89: 868-73(1996); Carmella, S. G., Borukhova, A., Akerkar, S. A. and Hecht, S. S. Analysis of human urine for pyridine-N-oxidemetabolites of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone, a tobacco-specific lung carcinogen. Cancer Epidemiol Biomarkers Prev. 6: 113-20(1997);及びWynder, E. L., And Muscat, J. E. The changing epidemiology of smoking and lung cancer histology. Environ Health Perspect.103 Suppl 8:143-148(1995))。   Nicotine, which is a typical harmful substance in tobacco, is nitrosamine-4- (methylnitrosamino) -1- (3-pyridyl) -1-butanone {nitrosamine-4 (methylnitrosamino), a substance that induces lung cancer. ) -1- (3-pyridyl) -1-butanone (NNK)}, a powerful environmental toxin. Symptoms of acute toxicity of nicotine induce pupil dilation, corneal opacity, vomiting, difficulty breathing, increased secretions in saliva and respiratory organs, decreased heart rate, etc. Systemic diseases (Brunneman, KD, Prokopezyk, B., Djordjevic, MV and Hoffmann, D. Formation and analysis of tobacco-specific N-nitrosamines. J. Natl. Cancer Inst. 89: 868-73 (1996); Carmella, SG, Borukhova, A., Akerkar, SA and Hecht, SS Analysis of human urine for pyridine-N-oxidemetabolites of 4- (methylnitrosamino) -1- (3-pyridyl) -1-butanone, a tobacco-specific lung Carcinogen. Cancer Epidemiol Biomarkers Prev. 6: 113-20 (1997); and Wynder, EL, And Muscat, JE The changing epidemiology of smoking and lung cancer histology. Environ Health Perspect. 103 Suppl 8: 143-148 (1995)) .

一方、ダイオキシン(Dioxin)は、生殖及び神経毒性、発癌を誘発する物質で、人類が作った最悪の毒劇物であって、ハロゲン化芳香族炭化水素のような作用により毒性を示し、最も強力なダイオキシンとして知られた2,3,7,8-テトラクロロ-ジベンゾ-パラダイオキシン(2,3,7,8-tetrachloro-dibenzo-p-dioxin)(TCDD)は、枯葉剤の主成分であって、内分泌撹乱性化合物質、すなわち環境ホルモンとして知られている(Poland, A. And Knutson, J. C. 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons; examination of the mechanism of Toxicol. Ann. Rev. Pharmacol. Toxico 22: 517-554(1982))。TCDDは、パルプ漂白過程、山火事、ゴミ焼却、自動車排気ガス、喫煙やその他の燃焼過程で発生するポリハロゲン化芳香族炭化水素(polyhalogenated aromatic hydrocarbon)であって、体内半減期が11年で、800〜850℃で熱分解される。TCDDは、消化管、呼吸器及び皮膚を通じて体内に吸収された後、細胞膜を通過して、細胞質に存在する芳香族炭化水素受容体(aromatic hydrocarbon receptor)及び熱ショックタンパク質(heat shock protein)の助力で細胞核に到達し、核内でDNAに作用して新しい酵素を生成させ、体重減少、免疫機能抑制、皮膚への毒性誘発、出産障害、肝機能と脂質代謝の異常、発癌などの毒性作用を誘発する内分泌系障害物質である(Safe, S. H. Comparative toxicology and mechanism of action of polychlorinate dibenzo-p-dioxins and dibenzofurans. ibid. 26: 371-399(1986);及びGelboin, H. V. Benzo(a)pyrene metabolism, activation and carcinogenesis:role and regulation of mixed-function oxidases and felated enzymes. Physiol, Rev. 60: 1107-1166(1980))。   On the other hand, dioxin is a substance that induces reproduction, neurotoxicity, and carcinogenesis. It is the worst poisonous and deleterious substance made by humans. It is toxic by the action of halogenated aromatic hydrocarbons and is the most powerful. 2,3,7,8-tetrachloro-dibenzo-p-dioxin (TCDD), known as a dioxin, is the main component of defoliants. Known as endocrine disrupting compounds, or environmental hormones (Poland, A. And Knutson, JC 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons; examination of the mechanism of Toxicol Ann. Rev. Pharmacol. Toxico 22: 517-554 (1982)). TCDD is a polyhalogenated aromatic hydrocarbon produced during pulp bleaching, forest fires, garbage incineration, automobile exhaust, smoking and other combustion processes, and has a half-life in the body of 11 years. Pyrolysis at 800-850 ° C. TCDD is absorbed into the body through the gastrointestinal tract, respiratory organs, and skin, and then passes through the cell membrane to help aromatic hydrocarbon receptors and heat shock proteins present in the cytoplasm. To reach the cell nucleus and act on DNA in the nucleus to generate a new enzyme, causing toxic effects such as weight loss, immune function suppression, induction of skin toxicity, birth defects, abnormal liver function and lipid metabolism, carcinogenesis, etc. Ibid. 26: 371-399 (1986); and Gelboin, HV Benzo (a) pyrene metabolism, Safe, SH Comparative toxicology and mechanism of action of polychlorinate dibenzo-p-dioxins and dibenzofurans. activation and carcinogenesis: role and regulation of mixed-function oxidases and felated enzymes. Physiol, Rev. 60: 1107-1166 (1980)).

ニコチン及びTCDDに対する毒性減少研究には、緑茶抽出物が肺ガンが誘導されたマウス(mouse)の癌発生を抑制し、NNKによる肺ガン発生を抑制する作用があり、ニコチンの環境ホルモンや各種重金属の毒性を除去するのに優れた効能があるという報告がある(Chung. F. L. The prevention of lung cancer induced by a tobacco-specific carcinogen in rodents by green and black Tea. Proc. Soc. Exp. Viol. Med. 220: 244-248(1999);及びFujiki, H., Suganuma, M., Okabe, S., Sueoka N., Komori, A., Sueoka, E., Kozu, T., Tada, Y., Suga, K., Imai, K. and Nakachi, K. Cancer inhibition by green tea. Mutat. Res. 18: 307-310(1998))。   In the study on the reduction of toxicity to nicotine and TCDD, green tea extract has the effect of suppressing the occurrence of lung cancer in mice in which lung cancer has been induced, and has the effect of suppressing the occurrence of lung cancer by NNK. (Chung. FL The prevention of lung cancer induced by a tobacco-specific carcinogen in rodents by green and black Tea. Proc. Soc. Exp. Viol. Med. 220: 244-248 (1999); and Fujiki, H., Suganuma, M., Okabe, S., Sueoka N., Komori, A., Sueoka, E., Kozu, T., Tada, Y., Suga , K., Imai, K. and Nakachi, K. Cancer inhibition by green tea. Mutat. Res. 18: 307-310 (1998)).

また、緑茶抽出物及び緑茶抽出物を含む植物抽出混合物がニコチンの分解力を増加させると知られている(Kyung, Y. J. and Lee, D. H. Enhanced conversion to cotinine from nicotine by green tea extract. Korean J. Environmental Agriculture. 19: 147-153(2000);及びKim, J. H., Lee, D. H., Cho, H. J. and Jeong, J. M. Effects of phyto-extract mixture on the nicotine decomposition. J. Fd Hyg. Safety. 17: 8-14(2002))。そして、TCDD及び類似化合物の生化学的反応は、肝臓のミクロソーム(microsome)に存在するサイトクロムP450複合体(cytochrome P450 complex)の合成増加に関するものであり、TCDDに対する毒性発現機作を酸化性ストレス(oxidative stress)誘発によるものと考え、これに関心を持って多くの研究が進行中にある(Kitchin, K. T. and Woods, J. S. 2,3,7,8-Tetrachlorodibenzo-p-dioxin effect on hepatic microsomal cytochromes p448-mediated activities. Toxicol. Appl. Phamacol. 47: 537-546(1979);及びMohammadpour, H., Murray, W. J. and Stohs, S. J. 2,3,7,8-Tetrachloro-dibenzo-p-dioxin(2,3,7,8-TCDD)-induced lipid Peroxidation in genetically responsive and non-responsive mice. Arch. Environ. Contam. Toxicol. 17: 645-650(1988))。   It is also known that green tea extract and plant extract mixture containing green tea extract increase nicotine degradability (Kyung, YJ and Lee, DH Enhanced conversion to cotinine from nicotine by green tea extract. Korean J. Environmental 19: 147-153 (2000); and Kim, JH, Lee, DH, Cho, HJ and Jeong, JM Effects of phyto-extract mixture on the nicotine decomposition. J. Fd Hyg. Safety. 17: 8-14 (2002)). The biochemical reaction of TCDD and similar compounds is related to the increased synthesis of cytochrome P450 complex present in liver microsomes, and the mechanism of toxic expression of TCDD is influenced by oxidative stress. (Kitchin, KT and Woods, JS 2,3,7,8-Tetrachlorodibenzo-p-dioxin effect on hepatic microsomal cytochromes p448-mediated activities. Toxicol. Appl. Phamacol. 47: 537-546 (1979); and Mohammadpour, H., Murray, WJ and Stohs, SJ 2,3,7,8-Tetrachloro-dibenzo-p-dioxin (2 , 3, 7, 8-TCDD) -induced lipid peroxidation in genetically responsive and non-responsive mice. Arch. Environ. Contam. Toxicol. 17: 645-650 (1988)).

本願発明者らは、特に、東醫寶鑑など伝統漢方医学書籍及び民間療法などで解毒機能があると知られた薬用植物のうち前述した現代の代表的毒性物質を解毒できる効果的な生薬を探すために鋭意研究し、その結果、いくつかの特定の薬用植物抽出物の混合組成物が体内ニコチン及びTCDDなどのダイオキシンの毒性を顕著に減少させることができることを知見し、本発明を完成した。   The inventors of the present application, in particular, are effective herbal medicines that can detoxify the above-mentioned typical representative toxic substances among the medicinal plants known to have a detoxifying function in traditional Chinese medicine books such as Tokankan and folk remedies. As a result of diligent research to find out, it was found that a mixed composition of several specific medicinal plant extracts can significantly reduce the toxicity of dioxins such as nicotine in the body and TCDD in the body, thus completing the present invention. .

本発明は、上記問題点に鑑みなされたものであり、ニコチン及びダイオキシンのような現代の代表的な毒性物質の体内解毒作用を持つ生薬抽出物で構成される組成物を提供することを目的とする。 The present invention has been made in view of the above problems, and an object of the present invention is to provide a composition comprising a herbal extract having an in vivo detoxifying action of typical representative toxic substances such as nicotine and dioxin. To do.

また本発明は、前記組成物の製造方法を提供することを他の目的とする。   Another object of the present invention is to provide a method for producing the composition.

前記目的を達成するために、本発明の第1の態様によれば、体内ニコチン及び/またはダイオキシン分解効果を有する、黒豆、蒲公英及び金銀花を含む生薬抽出物の混合組成物を提供することを特徴とする。 In order to achieve the above object, according to the first aspect of the present invention, there is provided a mixed composition of herbal extracts containing black beans, koei kan and gold and silver flowers, which have a body nicotine and / or dioxin degradation effect. Features.

本発明の第2の態様によれば、体内ニコチン及び/またはダイオキシン分解効果を有する、黒豆、蒲公英及び金銀花の生薬抽出物の混合物に、半夏生、決明子及び甘草からなる群から選ばれる1つまたはそれ以上の生薬抽出物をさらに含む組成物を提供することを特徴とする。   According to the second aspect of the present invention, the mixture of herbal extracts of black beans, koei kan and gold and silver flowers, which has a body nicotine and / or dioxin degrading effect, is selected from the group consisting of Hanatsusei, Seiko and licorice, or It is characterized by providing a composition further comprising a further herbal extract.

本発明の第3の態様によれば、前記本発明の第1及び第2の態様による生薬抽出物の混合組成物の製造方法を提供することを特徴とする。
本発明の第4の態様によれば、本発明の第1及び第2の態様による組成物を含む食品を提供することを特徴とする。
According to a third aspect of the present invention, there is provided a method for producing a mixture composition of herbal extracts according to the first and second aspects of the present invention.
According to the 4th aspect of this invention, the foodstuff containing the composition by the 1st and 2nd aspect of this invention is provided, It is characterized by the above-mentioned.

本発明による組成物は、周辺で容易く入手でき、人体に無害な生薬から容易に製造でき、過量服用時にも副作用を起こすこと無く、現代人の健康に深刻な被害を与える代表的毒性物質であるニコチン及びダイオキシンの体内毒性軽減に優れた効果を有する。   The composition according to the present invention is a typical toxic substance that can be easily obtained from herbal medicines that are easily available in the vicinity, can be easily manufactured from herbal medicines that are harmless to the human body, and causes serious damage to the health of modern people without causing side effects even when taken in an overdose It has an excellent effect on reducing in vivo toxicity of nicotine and dioxin.

まず、本発明による前記組成物を構成する各生薬の効能を昔から伝えられる民間療法または漢方医学関連書籍などに記載された事項に基づいて簡単に説明する。   First, the effect of each herbal medicine constituting the composition according to the present invention will be briefly described based on matters described in traditional folk remedies or Chinese medicine related books.

東醫寶鑑、本草綱目などによれば、黒豆(Glycine max Merrill)、すなわち黒い豆は、昔から解毒、活血、黄疸、浮腫、風痺、利尿などに効果があると知られている。したがって、韓国のように米を主食とする国では、黒い豆を入れて飯を炊いたり、又は食酢に漬けてからそのまま食べたり、他の穀類と一緒に蒸して粉に作って健康食の材料として使用したりなど、その効能により広く摂取されている食べ物である。しかし、黒豆自体がニコチンまたはダイオキシンの解毒に直接的な優秀な効果を示すとは全く予想しなかった。 According to Tokankan, Honsotsuna, etc., black beans (Glycine max Merrill), that is, black beans, have long been known to be effective in detoxification, live blood, jaundice, edema, numbness, diuresis and the like. Therefore, in countries such as Korea where rice is the staple food, rice is cooked with black beans, or soaked in vinegar and then eaten as is, or steamed with other cereals to make flour and ingredients for healthy food It is a food that is widely consumed due to its effectiveness, such as use as However, we never expected that black beans themselves would have a direct superior effect on nicotine or dioxin detoxification.

甘草(Glycyrrhiza uralensis)は、従来から「薬舗に甘草」という話がある程度にあらゆる薬材の材料としてほとんど欠けない物質としてよく知られていた。その具体的な効能については、東醫寶鑑などには、あらゆる薬の毒性を解毒し、72個の石薬と1200個の草薬を互いに調和して薬効をよく発現することから、あだ名を「国老」とすると述べられている。また、甘草は、特に、ショウガ、ナツメと一緒に各種毒を解くのに優れた効果があり、食中毒や各種薬物中毒、抗癌剤の毒を解くのに効果的であると記載されている。 Licorice (Glycyrrhiza uralensis) has long been well known as a substance that has almost lacked the story of “licorice in pharmacy” to some extent. As for its specific efficacy, Togakukan etc. is nicknamed because it detoxifies the toxicity of all drugs and expresses its efficacy in harmony with 72 stone drugs and 1200 herbs. It is said that it is "Kunio". In addition, licorice is described as having an excellent effect of detoxifying various poisons together with ginger and jujube, and effective in detoxifying food poisoning, various drug poisoning and anticancer drugs.

一方、前記黒豆と甘草の抽出物の混合使用は、カルバメイト(carbamate)中毒に対する解毒及び防御効果があるという報告がある(Shin, I. S., Min, K. J. and Kang, H. Y. A study on the preventive effect of extract of Glycyrrhizae Radix and Glycine semen on NAC intoxication. Kor. J. Env. Hlth. Soc. 19: 61-68(1993))。 On the other hand, there is a report that mixed use of the black bean and licorice extract has a detoxifying and protective effect against carbamate poisoning (Shin, IS, Min, KJ and Kang, HY study on the preventive effect of extract). of Glycyrrhizae Radix and Glycine semen on NAC intoxication. Kor. J. Env. Hlth. Soc. 19: 61-68 (1993)).

金銀花(Lonicerae flos)は、忍冬草の花であり、東醫寶鑑には、熱毒、血痢などに用いられ、解毒剤と消炎剤として風邪、嘔吐などを治療するに使われると記述されている。 The gold-silver flower (Lonicerae flos) is a flower of Shinobi Fuyusaku, and it is used by Tokankan for heat poison, diarrhea, etc., and as an antidote and anti-inflammatory agent for treating colds, vomiting, etc. Has been.

蒲公英(Taraxacum mongolicum)は、蒲公草とも呼ばれ、タンポポを指すものであり、東醫寶鑑には、 熱毒を化し、悪瘡を治り、凝りをほぐし、食毒を解き、滞気を散じるに効能を発現すると記載されている。また、中国中薬大辞典には、解熱、解毒、利尿、催乳効果があり、炎症、でき物を治し、肝、胆嚢治療に利用すると記述している。また、本草綱目には、タンポポの汁を継続的に飲めば、髪の毛が黒くなり、胃と骨が丈夫になると記されており、このような蒲公英と金銀花抽出物の混合使用が抗炎症効果に優れているとの報告がある(Hong, S. J., Choi, E. G., Lim, H. S., Shon, J. B. and Jeong S. S. Effect of herbal dentifrice on dental plaque and gingivitis. J Korean Acad Dental Health. 25: 347-355(2001))。 Taraxacum mongolicum, also called 蒲 公 草, refers to the dandelion, and in the eastern ginseng, it turns into a heat poison, cures pressure sores, relieves stiffness, dissolves food poison, It is described that it has an effect to disperse. In addition, the Chinese Medicinal Dictionary has effects of antipyretic, detoxification, diuresis, and lactation, and it is said that it cures inflammation and artifacts and is used to treat the liver and gallbladder. In addition, it is noted that if you take dandelion juice continuously, your hair will become darker and your stomach and bones will be stronger. (Hong, SJ, Choi, EG, Lim, HS, Shon, JB and Jeong SS Effect of herbal dentifrice on dental plaque and gingivitis. J Korean Acad Dental Health. 25: 347-355 ( 2001)).

半夏生(Saururus chinensis)は、中国の本草学の本に、水腫と脚気を治療し、大小便をよく通し、痰を切り、詰りを解消し、腹中の塊りを解き、でき物や腫脹を治療すると記されている。その他、中国薬学大辞典、中国医学大辞典、 唐草本、嶺南採薬録、本草推陣などにも、水腫と脚気を治療し、便通をよくし、抗菌、解毒、消炎作用があると記されている。 Saururus chinensis is a Chinese herbology book that treats edema and beriberi, passes large and small stools, cuts heels, clears clogs, breaks up masses in the abdomen, treats things and swelling Then it is written. In addition, the Chinese Pharmacy Dictionary, Chinese Medicine Dictionary, Karakusa, Shonan Yakuhin, and Honso Jinjin also treat edema and beriberi, improve bowel movement, and have antibacterial, detoxification, and anti-inflammatory effects. ing.

決明子は、目を明らかにする茶としてよく知られている生薬である。東醫寶鑑には、決明子は、肝気を補い、浄水を流して、頭痛と鼻血を治し、東醫薬学には、肝熱による頭痛の治療や、目の充血、疼痛、流涙の治療に利用し、また、視力増進に利用すると記述されている。また、薬用植物辞典には、利尿、消化不良、胃腸病などに有効であり、視力を良くすると記載されている。 Seiko is a herbal medicine well known as a tea that reveals eyes. For Tojokan, Akemiko supplemented the liver and flushed with water to treat headache and nosebleed. For Tojo Pharmacy, healed headaches with liver fever, redness of eyes, pain and tears. It is described that it is used for visual acuity and for visual acuity enhancement. In addition, the medicinal plant dictionary describes that it is effective for diuresis, indigestion, gastrointestinal disease, etc. and improves visual acuity.

一方、自然民間療法及び漢方医学では、前記半夏生(Saururus chinensis)及び決明子(Cassia obtusifolia)を共に使用すれば、利尿及び解毒に優れた効果があると知られている(Shin, I. S., Min, K. J. and Kang, H. Y. A study on the preventive effect of extract of Glycyrrhizae Radix and Glycine semen on NAC intoxication. Kor. J. Env. Hlth. Soc. 19: 61-68(1993); Hong, S. J., Choi, E. G., Lim, H. S., Shon, J. B. and Jeong S. S. Effect of herbal dentifrice on dental plaque and gingivitis. J Korean Acad Dental Health. 25: 347-355(2001);李尚仁,安徳均,韓方家族療法大全(漢方薬,漢方療法,民間療法),慶熙大漢医科大学本草学教室編,韓国図書出版中央会.970-971, 981-983(1994))。 On the other hand, in natural folk remedies and traditional Chinese medicine, it is known that the use of both the Saururus chinensis and the Cassia obtusifolia has an excellent effect on diuresis and detoxification (Shin, IS, Min, KJ and Kang, HY A study on the preventive effect of extract of Glycyrrhizae Radix and Glycine semen on NAC intoxication.Kor. J. Env. Hlth. Soc. 19: 61-68 (1993); Hong, SJ, Choi, EG, Lim , HS, Shon, JB and Jeong SS Effect of herbal dentifrice on dental plaque and gingivitis. J Korean Acad Dental Health. 25: 347-355 (2001); , Folk remedies), Kyunghee University of Herbal Medicine, Department of Herbal Sciences, Korean Book Publishing Central Association. 970-971, 981-983 (1994)).

以上記載した通り、本願発明者らは、伝統漢方医学書籍や昔から伝えられている民間療法などにより、従来から各種解毒や利尿作用があると知られた生薬を、発明を構成する主要構成成分として選択し、本発明を完成するに至った。しかしながら、前記した通り、前記生薬各々がある程度の解毒や利尿、及び適切な消炎作用を有し、体内代謝を活発にするという一般的な事実は知られているが、そのような効能や効果が、現代社会で深刻な健康上の問題を起こす代表的毒性物質であるニコチンとダイオキシンの体内解毒に特に優れた効果を発揮するという点は誰も容易に予想しなかった。また、前記生薬それぞれの抽出物を単独で使用する場合には、本発明の第1または第2の態様による組成物のような顕著な解毒効果を達成できず、つまり、これは、前記生薬の単純な選択または湊合だけでは本発明を達成できないことを立証するものである。また、このような事実は、以下の本発明の実施例で詳細に記載するように、ニコチン及びダイオキシン急性毒性試験などのような実験により十分に立証されることができ、このような試験及びその結果に対して考察しなくては、前記した特定組成物のニコチン及びダイオキシンに対する解毒効果を立証することができないばかりでなく、本発明をも完成できない。 As described above, the inventors of the present invention are the main constituents constituting the invention of herbal medicines conventionally known to have various detoxification and diuretic effects by traditional Chinese medicine books and traditional folk remedies. As a result, the present invention was completed. However, as described above, the general fact that each herbal medicine has a certain degree of detoxification, diuresis, and appropriate anti-inflammatory action and activates metabolism in the body is known. No one easily anticipated that nicotine and dioxin, the representative toxic substances that cause serious health problems in modern society, would have particularly good effects on in-vivo detoxification. In addition, when the extracts of each of the herbal medicines are used alone, a significant detoxification effect as in the composition according to the first or second aspect of the present invention cannot be achieved, that is, It proves that the present invention cannot be achieved by simple selection or combination. Such facts can also be well established by experiments such as nicotine and dioxin acute toxicity tests, as described in detail in the examples of the invention below, and such tests and their Without considering the results, it is not only possible to demonstrate the detoxification effect of the specific composition described above on nicotine and dioxin, but also the present invention cannot be completed.

以下、本発明を詳細に説明する。
まず、本発明による組成物の製造方法は、前記第1または第2の態様によるそれぞれの生薬を洗浄、乾燥し、細切りした後、生薬の重量の約10〜30倍程度のエタノールを添加して、30〜50℃で30〜50時間程度還流抽出することによって、各生薬抽出液を得、これらを各々所定の固形分含量になるまで減圧濃縮することによって、各生薬抽出エキスを得、かくして得られた抽出エキスを各々凍結乾燥することによって、各生薬抽出物の粉末を得た後、これらの粉末を成分に応じて一定量ずつ混合して製造することができる。ここで、この技術分野における通常の知識を有する者なら、生薬抽出のための還流時において還流時間は、還流温度によって適宜調節できることが分かる。
Hereinafter, the present invention will be described in detail.
First, in the method for producing the composition according to the present invention, each herbal medicine according to the first or second aspect is washed, dried, chopped, and then added with about 10 to 30 times the weight of the herbal medicine. , Each crude drug extract is obtained by reflux extraction at 30-50 ° C. for about 30-50 hours, and each herb extract is obtained by concentrating them under reduced pressure until a predetermined solid content is obtained. Each extract obtained can be freeze-dried to obtain powder of each herbal extract, and then these powders can be mixed and produced in a certain amount according to the components. Here, a person having ordinary knowledge in this technical field understands that the reflux time can be appropriately adjusted according to the reflux temperature when refluxing for extracting the herbal medicine.

又は、前記方法で得られた各生薬抽出物を凍結乾燥して粉末化する前に、各抽出液を所定の濃度で減圧濃縮するか、または濃縮しない状態で、一定量ずつ混合して使用することができる。すなわち、本発明による生薬抽出物の混合組成物は、各生薬抽出原液、またはこれを所定の固形分含量で濃縮した抽出エキス、またはこれらの抽出物を凍結乾燥した乾燥粉末のうち任意の形態で、互いに一定割合で混合して使用することができる。   Or before freeze-drying each herbal extract obtained by the above method into a powder, each extract is concentrated under reduced pressure at a predetermined concentration, or a certain amount is mixed and used without concentration. be able to. That is, the mixture composition of the herbal extracts according to the present invention is in any form of each crude drug extract stock solution, an extract obtained by concentrating the crude drug extract with a predetermined solid content, or a dry powder obtained by freeze-drying these extracts. , And can be mixed and used at a certain ratio.

本発明による組成物は、好ましくは、各生薬抽出物が同一の固形分含量で減圧濃縮された状態、またはこれらを凍結乾燥して粉末化した状態を基準にして、黒豆抽出物約1〜20重量部、蒲公英抽出物約5〜30重量部、及び金銀花抽出物約5〜30重量部を混合して製造することができ、これに、本発明の第2の態様により決明子、甘草、または半夏生がさらに含有される場合、決明子抽出物を約5〜30重量部、甘草抽出物を約1〜20重量部、及び半夏生抽出物を約10〜50重量部の範囲でさらに含むことができる。   The composition according to the present invention preferably has about 1 to 20 black bean extracts on the basis of the state where each herbal extract is concentrated under reduced pressure with the same solid content or lyophilized into powder form. Parts by weight, about 5 to 30 parts by weight of the extract of cocoon, and about 5 to 30 parts by weight of the gold and silver flower extract can be mixed. When semi-summer is further contained, it may further include about 5 to 30 parts by weight of Keriko extract, about 1 to 20 parts by weight of licorice extract, and about 10 to 50 parts by weight of semi-summer extract.

この技術分野における通常の知識を有する者なら、各生薬抽出物が上述したような同一の固形分含量で濃縮された抽出エキス、またはそれから凍結乾燥された粉末状態でなくとも、各生薬抽出物の濃度に応じて、抽出物の含量が前記のような比率になるように適宜調節して混合することによって、本発明による組成物を製造できることが理解できるだろう。   Those having ordinary knowledge in this technical field need to know whether each herbal extract is concentrated in the same solid content as described above, or is not lyophilized powder. It will be understood that the composition according to the present invention can be produced by adjusting the content of the extract to a ratio as described above according to the concentration.

本発明による組成物は、特に、経口投与することが望ましく、服用が便利になるように色々な形態で製剤化することができる。すなわち、抽出物エキスの混合物を使い捨て用容器などに込めて随時服用できるようにしたり、混合粉末を適当な担体と一緒にカプセルまたは錠剤のような形態で製剤して簡便に服用するようにすることができる。   The composition according to the present invention is particularly desirable to be administered orally, and can be formulated in various forms for convenient administration. That is, a mixture of the extract extract can be taken in a disposable container or the like, or can be easily taken by formulating the mixed powder together with an appropriate carrier in the form of a capsule or a tablet. Can do.

本発明による組成物は、前記した通り、抽出エキスまたは粉末の混合物をそのまま、または適当な担体と一緒に製剤して一日一定量ずつ服用するようにすることができるが、他の実施例では、前記組成物を食品に添加して日常的に摂取するようにすることができる。すなわち、前記組成物を飲み物やゼリー、キャンディ、ガム、スナックや菓子類などに添加して摂取したり、または水や牛乳などに混ぜて飲むようにする健康補助食品の形態で製造することもできる。   As described above, the composition according to the present invention can be used as an extract or a mixture of powders as it is or formulated together with a suitable carrier so that it can be taken in a certain amount every day. The composition can be added to foods and taken on a daily basis. That is, the composition may be added to drinks, jelly, candy, gum, snacks, confectionery, etc. to be ingested or mixed with water or milk to be produced in the form of a health supplement. .

本発明による組成物は、前記した混合粉末状態を基準にして、体重1kg当たり一日350mg以上、より好ましくは400mg以上服用する場合、体内ニコチン及び/またはダイオキシンの顕著な解毒効果を発揮することを発見した。350mg以下で服用する場合には、解毒効果がそれほど高く発現されなかった。一方、前記組成物は、各生薬がいずれも食薬庁で食用として許可された植物であるか、または大部分が日常でしばしば摂取、服用する植物の抽出物からなるので、前記した一日投与量を超過して過量服用しても、毒性など副作用は全く起こらない。   The composition according to the present invention exhibits a significant detoxifying effect of nicotine and / or dioxin in the body when taken at 350 mg or more, more preferably 400 mg or more per kg body weight per day based on the above mixed powder state. discovered. When taken at 350 mg or less, the detoxification effect was not so high. On the other hand, since each of the herbal medicines is a plant that is approved for consumption by the Pharmacopeia, or most of the composition is an extract of a plant that is often ingested and taken on a daily basis, If the dose is overdose, no side effects such as toxicity will occur.

以下、本発明による前記組成物の製造方法及びその効果を実施例に基づいて詳細に説明する。これらの実施例は、本発明を説明するためのもので、本発明を限定するものではない。 Hereinafter, the manufacturing method of the said composition by this invention and its effect are demonstrated in detail based on an Example. These examples serve to illustrate the invention and do not limit the invention.

生薬抽出物の抽出及び抽出物粉末の製造   Extraction of herbal extract and manufacture of extract powder

黒豆、金銀花、蒲公英、決明子、半夏生、及び甘草を韓国の市場で購買して、各々500gずつ細切りした後、生薬毎に各々40%エタノール10Lずつを添加し、40℃で48時間還流抽出した。かくして得られた各生薬抽出液を、固形分の含量が25%になるまで40℃で減圧濃縮した後、凍結乾燥して各生薬抽出物の粉末を得た。   Purchasing black beans, gold and silver blossoms, Koei Hou, Seiko, Hankao, and licorice in the Korean market, chopping each 500 g, adding 10 L of 40% ethanol for each herbal medicine, and reflux extraction at 40 ° C. for 48 hours . Each crude drug extract thus obtained was concentrated under reduced pressure at 40 ° C. until the solid content was 25%, and then freeze-dried to obtain a powder of each crude drug extract.

これらの生薬抽出物の粉末は、本発明の実施例によって粉末を蒸留水など担体と一緒に、または錠剤の形態で製剤して使用した。そして、各生薬毎に、または2種以上の生薬抽出物の粉末を混合使用して、その効果を比較した。

ニコチン急性毒性試験方法
The powders of these herbal extracts were used according to the examples of the present invention by formulating the powder together with a carrier such as distilled water or in the form of a tablet. And the effect was compared for each herbal medicine or mixing and using the powder of 2 or more types of herbal extracts.

Nicotine acute toxicity test method

体重約12±2gの3週齢雄ICRマウス(サムタコ社、韓国京畿道烏山市所在)22匹を、対照群及び処理群用に各々11匹ずつ分け、1週間飼育環境に適応させた後、実験に使用した。   After 22 male 3-week-old male ICR mice weighing about 12 ± 2 g (Samutako, located in Ulsan City, Gyeonggi-do, Korea) were divided into 11 for each of the control group and the treatment group, and adapted to the breeding environment for 1 week. Used for experiment.

マウス飼育は、温度22±1℃、湿度55±5%、換気回数12回/日、明暗周期12時間/日(朝8時点灯、夜8時消灯)で設定された環境で、ケージ当たり1匹ずつ収容して、マウス用粉末飼料(サムタコ社、製品番号:Sam#31)を水と共に摂取させることによって行った。   Mice are kept in an environment set at a temperature of 22 ± 1 ° C, a humidity of 55 ± 5%, a ventilation rate of 12 times / day, and a light / dark cycle of 12 hours / day (lights on at 8 am, lights off at 8 pm). Each mouse was housed and the powdered feed for mice (Samuco, product number: Sam # 31) was ingested with water.

この際、処理群マウスには、本発明による6種の生薬抽出物の粉末を全て同量ずつ混合した粉末(以下、混合粉末Aという)を、飼料1日摂取量約4gの10%に該当する400mgずつを飼料に添加して、4週齢から1週間給餌し、対照群は、同量の粉末飼料だけを給餌した。   At this time, the treated group of mice corresponds to 10% of the daily intake of about 4 g of feed, which is a mixture of the same amount of the powders of the six kinds of herbal extracts according to the present invention (hereinafter referred to as mixed powder A). 400 mg each was added to the feed and fed for 1 week from 4 weeks of age, and the control group fed only the same amount of powdered feed.

一方、予備実験で、対照群マウスに対するニコチン致死量を決定した。このために、ニコチン酒石酸塩(nicotine tartarate salt)(Sigma No.N5260)の中で純粋ニコチン量で42mg/kgを0.9%生理食塩水に溶解した後、これを0.45μLシリンジ濾過器(syringe filter)を介してろ過して使用した。前記した試験飼料(サムタコ社、製品番号:Sam#31)を1週間給餌後、5週齢マウス腹腔内にニコチンを投与し、麻痺開始時間、発作開始及び終了時間、そして死亡するまでの時間を測定した。

人体内でのニコチン解毒効果の確認方法
On the other hand, the nicotine lethal dose for the control group mice was determined in a preliminary experiment. For this purpose, 42 mg / kg of nicotine tartarate salt (Sigma No. N5260) in a pure nicotine amount was dissolved in 0.9% physiological saline, and this was then added to a 0.45 μL syringe filter ( Syringe filter) was used. After feeding the test feed (SamTako, product number: Sam # 31) for 1 week, nicotine is administered into the abdominal cavity of a 5-week-old mouse, and the time to start paralysis, the start and end time of seizure, and the time until death It was measured.

Confirmation method of nicotine detoxification effect in human body

喫煙は、直接またはタバコの煙を通じて多くの危害性物質を流入させ、特に、このような危害性物質のうちニコチンは、体内代謝によりNNK等の発癌物質を生成する前駆体として利用される。最近の報告によれば、ニコチンの主代謝産物であるコチニンは、安定した物質であると同時に、NNKの活性及び形成を抑制すると知られている(Trushin, N., Hecht, S. S. Strereoselective metabolism of nicotine tobacco-specific N-nitrosamines to 4-hydroxy-4-(3-pydidyl) butanoic acid in rats. Chem Res Toxicol.
12: 163-71(1998))。
Smoking allows many harmful substances to flow in directly or through tobacco smoke. In particular, nicotine among these harmful substances is used as a precursor for producing carcinogens such as NNK by metabolism in the body. According to a recent report, cotinine, the main metabolite of nicotine, is known to be a stable substance and at the same time suppress NNK activity and formation (Trushin, N., Hecht, SS Strereoselective metabolism of nicotine). tobacco-specific N-nitrosamines to 4-hydroxy-4- (3-pydidyl) butanoic acid in rats.Chem Res Toxicol.
12: 163-71 (1998)).

人体内でのニコチンの解毒効果を確認するために、前記した混合粉末Aを1日摂取量1,000mgが含まれた錠剤で製造した。また、この際、上述したように、本発明による6種の生薬抽出物それぞれの効果と2種以上の生薬抽出物の混合物の効果とを比較するために、各々1種の生薬抽出物の粉末だけを含む錠剤と、2種以上の生薬抽出物の粉末を組合して含む錠剤とを製造した。この際、1つの錠剤内に含有される生薬抽出物粉末の総量は、1,000mgになるようにした。このように製造された錠剤を、後述する方法によって被試験者に服用させることによって、人体内でのニコチン解毒力を測定した。   In order to confirm the detoxification effect of nicotine in the human body, the aforementioned mixed powder A was produced as a tablet containing a daily intake of 1,000 mg. At this time, as described above, in order to compare the effect of each of the six kinds of herbal extracts according to the present invention with the effect of the mixture of two or more kinds of herbal extracts, each powder of one kind of herbal extract is used. And tablets containing a combination of two or more herbal extract powders. At this time, the total amount of the herbal extract powder contained in one tablet was set to 1,000 mg. The nicotine detoxification ability in the human body was measured by allowing the test subject to take the tablet thus produced by the method described later.

被試験者は、一日平均喫煙量が1箱以上である20〜30才の壮健な男性11人を対象にした。被試験者は、尿採取と同時に錠剤を服用し、服用3日目、及び1週間間隔で午前10時に尿を採取し、約1ヶ月間尿中のコチニン(cotinine)を定量することで、前記した錠剤の服用前及び服用後の体内ニコチン量の変化を確認した。   The test subjects were 11 healthy men aged 20-30 with an average daily smoking amount of 1 box or more. The test subject took a tablet at the same time as urine collection, collected urine on the third day of administration, and at 10 am at weekly intervals, and quantified cotinine in the urine for about one month. The change in the amount of nicotine in the body before and after taking these tablets was confirmed.

ニコチンは、半減期が30〜60分程度で、半減期が15時間であるコチニンに比べて非常に不安定するため、分析誤差を低減できる尿中のコチニン量を分析し、ニコチン解毒力を推定する方法を使用した(Peach, H., Ellard, G. A., Jenner, P. J. and Morris, R. W. A simple inexpensive urine test of smoking. Thorax. 40: 351-357(1985))。スタティスティックス(Statistix)を用いて信頼限界(C.I.:Confidence interval)を求め、95%信頼限界で比較した(Statistix. Statistix for Windows. User’s Manual, Analytical software. USA.(1996))。

コチニン定量法
Nicotine is very unstable compared to cotinine, which has a half-life of about 30 to 60 minutes and a half-life of 15 hours. Therefore, nicotine detoxification power is estimated by analyzing the amount of urinary cotinine that can reduce analysis errors. (Peach, H., Ellard, GA, Jenner, PJ and Morris, RW A simple inexpensive urine test of smoking. Thorax. 40: 351-357 (1985)). Confidence interval (CI) was calculated using Statistix and compared with 95% confidence limit (Statistix. Statistix for Windows. User's Manual, Analytical software. USA. (1996)) .

Cotinine assay

Barlowなどの方法(Barlow, R. D., Thompson, P. A.and Stone, R. B. Simultaneous determination of nicotine, cotinine and five additional nicotine metabolite in the urine of smokers using pre-column derivatisation and HPLC. B. J. Chromatogr. 419: 375-380(1987))により尿中のコチニン量を測定した。   Barlow et al. (Barlow, RD, Thompson, PAand Stone, RB Simultaneous determination of nicotine, cotinine and five additional nicotine metabolite in the urine of smokers using pre-column derivatisation and HPLC. BJ Chromatogr. 419: 375-380 (1987 )), The amount of cotinine in urine was measured.

すなわち、前記のように、各試験対象から採取した尿を、450xgで10分間遠心分離した後、上澄み液200μLをマイクロチューブ(microtube)に入れ、4M酢酸ナトリウム緩衝液(sodium acetate buffer)(pH4.7)100μL、1.5Mシアン酸カリウム(potassium cyanate)40μL、0.4Mクロラミン-T(chloramine-T)40μL、50%(v/v)アセトニトリル(acetonitrile)で製造した78mMバルビツール酸(barbituric acid)200μLを順に添加した後、10秒間混合した。この混合物を常温で15分間反応させ、1Mピロ亜硫酸ナトリウム(sodium metabisulphite)40μLで反応を中止させた後、490nmで吸光度を測定し、コチニンを定量した。

ダイオキシン急性毒性試験方法
That is, as described above, urine collected from each test subject was centrifuged at 450 × g for 10 minutes, and then 200 μL of the supernatant was put into a microtube, and 4M sodium acetate buffer (pH 4. 7) 100 μL, 1.5 M potassium cyanate 40 μL, 0.4 M chloramine-T 40 μL, 50 mM (v / v) 78 mM barbituric acid prepared with acetonitrile ) 200 μL was added in order and then mixed for 10 seconds. This mixture was reacted at room temperature for 15 minutes, and the reaction was stopped with 40 μL of 1M sodium metabisulphite, and then the absorbance was measured at 490 nm to quantify cotinine.

Dioxin acute toxicity test method

体重約200±20gの3週齢雄ラット(rat)TcnN(SD)BRラット(サムタコ社、韓国京畿道烏山市)40匹を購入し、5つの群に対して各群当たり8匹ずつ分けて、7日間適応させた後、実験に使用した。   Purchase 40 rats of 3 weeks old male rats (rat) TcnN (SD) BR (Sam Taco Co., Ulsan, Gyeonggi-do, Korea) weighing about 200 ± 20g. After 7 days of adaptation, it was used for experiments.

試験動物の飼育は、温度22±1℃、湿度55±10%、換気回数12回/日、明暗周期12時間/日(午前8時点灯、午後8時消灯)で設定された環境で、ラットケージ当たり1匹ずつ飼育し、飼料は、ラット用固形飼料を水と共に自由に摂取させた。   The test animals are raised in an environment set at a temperature of 22 ± 1 ° C., a humidity of 55 ± 10%, a ventilation rate of 12 times / day, and a light / dark cycle of 12 hours / day (lights on at 8 am, lights off at 8 pm). One animal was raised per cage, and the rat chow was freely fed with water.

ダイオキシン(Dioxin)は、TCDD(AccuStandard Co., USA)を使用し、TCDD 1mgを25μL DMSOとアセトン225μLに溶かした後、2.25mLのトウモロコシ油に希釈して使用した。本発明による6種の生薬抽出物の粉末を全て同量混合して製造した混合粉末Aは、400mg/kg/dayの濃度で蒸留水に溶解した後、経口投与した。   Dioxin was used by using TCDD (AccuStandard Co., USA) and dissolving 1 mg of TCDD in 25 μL of DMSO and 225 μL of acetone, and then diluting it in 2.25 mL of corn oil. A mixed powder A produced by mixing the same amount of all the six kinds of herbal extract powders according to the present invention was orally administered after being dissolved in distilled water at a concentration of 400 mg / kg / day.

図1に示すように、第1の群(対照群)には、生理食塩水(0.4mL)を、第2の群(担体投与群)にはアセトン、DMSO、及びトウモロコシ油が含有された担体だけを、第3の群(TCDD単独投与群)は、ラットの体重1Kg当たり5.0μgの濃度でTCDDを含む生理食塩水0.4mLを腹腔注射した。第4の群(混合粉末A前投与群)に対しては、TCDD1次腹腔注射7日前から混合粉末Aを経口投与し、第5の群(混合粉末A同時投与群)に対しては、TCDD1次腹腔注射と同時に混合粉末Aを経口投与したが、これらのTCDD注射量は、第3の群と同一にラット体重1Kg当たり5.0μgの濃度でTCDDを含む生理食塩水0.4mLにした。生理食塩水及びTCDD注射は、1週間隔で2回にかけて投与した。   As shown in FIG. 1, the first group (control group) contained physiological saline (0.4 mL), and the second group (carrier administration group) contained acetone, DMSO, and corn oil. The carrier alone, the third group (TCDD single administration group) was injected intraperitoneally with 0.4 mL of saline containing TCDD at a concentration of 5.0 μg per kg body weight of the rat. For the fourth group (premixed powder A pre-administered group), the powdered powder A was orally administered 7 days before the first intraperitoneal injection of TCDD, and for the fifth group (mixed powder A co-administered group), TCDD1 Simultaneously with the next peritoneal injection, the mixed powder A was orally administered, and the amount of these TCDD injections was set to 0.4 mL of physiological saline containing TCDD at a concentration of 5.0 μg per 1 kg body weight of the rat as in the third group. Saline and TCDD injections were administered twice at 1 week intervals.

2次腹腔注射1週間後、ラットをエチルエーテル(ethyl ether)で麻酔させ、心臓で全血した後、血液、肝臓、すい臓、腎臓、及び心臓機能に対する臨床数値を分析した。また、この際、スタティスティックス(Statistix)を用いて各群間にアノバ(ANOVA)でp<0.05水準で最小有意差検定(least significant difference test, LSD)をした(Statistix. Statistix for Windows. User’s Manual, Analytical software. USA. (1996))。   One week after the secondary peritoneal injection, the rats were anesthetized with ethyl ether and whole blood was collected from the heart, and then clinical values for blood, liver, pancreas, kidney, and heart function were analyzed. At this time, the least significant difference test (LSD) was performed at the p <0.05 level with nova (ANOVA) between each group using Statistix (Statistix. Statistix for Windows. User's Manual, Analytical software. USA. (1996)).

人体内でのニコチン解毒力による生薬抽出物の効果比較 Comparison of the effects of herbal extracts by nicotine detoxification in the human body

前記のように、本発明による6種の生薬抽出物のうち1種を含むものと、2種以上の生薬抽出物の混合物を含むものとの解毒効果を比較するために、前記各抽出物の粉末または2種以上の抽出物の混合粉末を錠剤当たり総1,000mgずつ含む錠剤を製造した。製造された錠剤を、前記人体内でのニコチン解毒効果の確認方法で説明したように被試験者に各々服用させることによって、人体内でのニコチン解毒効果を測定、比較した。   As described above, in order to compare the detoxification effect between one containing six kinds of herbal extracts according to the present invention and one containing a mixture of two or more kinds of herbal extracts, Tablets containing a total of 1,000 mg of powder or mixed powder of two or more extracts per tablet were produced. As described in the method for confirming the nicotine detoxification effect in the human body, each test subject took each of the manufactured tablets to measure and compare the nicotine detoxification effect in the human body.

図2は、これらのうち、特に、(1)黒豆、蒲公英、金銀花の抽出物粉末を各々1,000mgずつ含む錠剤;(2)黒豆と蒲公英、黒豆と金銀花、及び蒲公英と金銀花のように2種の生薬抽出物粉末を各々500mgずつ、総1,000mg含む錠剤、(3)黒豆、蒲公英、金銀花の3種の混合物粉末を各々約333mgずつ、総999mg含む錠剤、及び(4)黒豆、蒲公英、金銀花に決明子または甘草を追加に混合して4種の生薬抽出物の粉末を各々250mgずつ、総1,000mg含む錠剤、そして(5)黒豆、蒲公英、金銀花、半夏生、決明子及び甘草の6種の生薬抽出物の粉末を全て同量で混合して総1,000mg含む錠剤を服用した場合の効果を比較して示した棒グラフである。   Among these, FIG. 2 shows, in particular, (1) tablets containing 1,000 mg each of black bean, cocoon and gold and silver flower extract powders; (2) black beans and cocoon, black beans and gold and silver flowers; (3) tablets containing about 333 mg each of three kinds of mixture powders of black beans, koei ei, gold and silver flowers, and 999 mg in total, and (4) ) Tablets containing 250 mg each of 4 kinds of herbal extract powders with a total of 1,000 mg mixed with black beans, koei kan, gold and silver flowers, and (5) black beans, koei kan, gold and silver flowers, semi-summer, It is the bar graph which compared and showed the effect at the time of taking the tablet which mixes all the powder of 6 types of herbal medicines of Keriko and licorice at the same quantity, and contains a total of 1,000 mg.

前記グラフは、各々6個の棒からなる11個の棒群で構成される。各棒群において6個の棒は、前記各錠剤の服用日から0日、3日、1週間、2週間、3週間及び4週間目になる日に同じ錠剤を服用した11人の被試験者の尿から測定したコチニン濃度の平均値を示す。   The graph is composed of 11 bar groups each consisting of 6 bars. In each bar group, 6 bars are 11 test subjects who took the same tablet on the 0th day, 3rd day, 1st week, 2nd week, 3rd week, and 4th week from the day of taking each tablet. The average value of the cotinine concentration measured from urine was shown.

したがって、各棒群は、錠剤の種類による尿中のニコチン分解程度を比較できる指標となる。すなわち、前記グラフにおいて、横軸に各棒群の下側に記載されたように、第1の棒群は、「黒豆」抽出物だけを含む錠剤を服用した場合であり、第2の棒群は、「蒲公英」抽出物だけを含む錠剤を服用した場合であり、第3の棒群は、「金銀花」抽出物だけを含む錠剤を服用した場合であり、第4の棒群は、「黒豆と蒲公英」抽出物の混合物を含む錠剤を服用した場合であり、第5の棒群は、「黒豆と金銀花」抽出物の混合物を含む錠剤を服用した場合であり、第6の棒群は、「蒲公英と金銀花」抽出物の混合物を含む錠剤を服用した場合であり、第7の棒群は、「黒豆、蒲公英、金銀花」の3種の抽出物の混合物を含む錠剤を服用した場合であり、第8の棒群は、「黒豆、蒲公英、金銀花及び半夏生」の4種の抽出物の混合物を含む錠剤を服用した場合であり、第9の棒群は、「黒豆、蒲公英、金銀花及び決明子」の4種の抽出物の混合物を含む錠剤を服用した場合であり、第10の棒群は、「黒豆、蒲公英、金銀花及び甘草」の4種の抽出物の混合物を含む錠剤を服用した場合であり、第11の棒群は、「黒豆、蒲公英、金銀花、半夏生、決明子及び甘草」の6種の生薬抽出物を全て含む錠剤を服用した場合の、尿中のコチニン濃度を測定した結果を示す。   Therefore, each bar group serves as an index for comparing the degree of nicotine degradation in urine according to the type of tablet. That is, in the graph, as described on the lower side of each bar group on the horizontal axis, the first bar group is a case where a tablet containing only the “black bean” extract is taken, and the second bar group Is the case of taking a tablet containing only the “Kong Koei” extract, the third group of bars is the case of taking a tablet containing only the “gold and silver flower” extract, and the fourth group of bars is “ The case of taking tablets containing a mixture of “black beans and 蒲公英” extract, the fifth group of bars is the case of taking tablets containing a mixture of “black beans and gold and silver flowers” extract, the sixth group of bars Is the case of taking a tablet containing a mixture of “Kong Koei and Golden Silver Flower” extract, and the seventh bar group is taking a tablet containing a mixture of three kinds of extracts “Black Bean, Xin Ying Kim, Gold and Silver Flower” The eighth group of sticks is a tablet containing a mixture of four kinds of extracts of “black beans, koei rin, gold and silver flowers and semi-summer”. The ninth bar group is the case of taking a tablet containing a mixture of four kinds of extracts of “black beans, Koei Sakaki, golden silver flowers, and Akemiko”, and the tenth bar group is “black beans” In the case of taking a tablet containing a mixture of four kinds of extracts, “Kimei, Jinyin, Golden Silver Flower and Licorice”, the eleventh bar group is six kinds of “Black Bean, Jin Yin, Golden Silver Flower, Semi-Summer, Koseko and Liquorice” The result of having measured the urinary cotinine density | concentration at the time of taking the tablet containing all the crude drug extracts of is shown.

前記グラフから分かるように、6種の生薬抽出物を全て含む錠剤を服用した時(第11の棒群)が、服用前(0日目)と比較して服用後3日目となる日の尿中のコチニン濃度が最も高かった。次に、「黒豆、蒲公英、金銀花」の以外に1種の生薬抽出物をさらに含む錠剤を服用した場合(第8、第9、第10の棒群)が、錠剤服用後3日目となる日のコチニン濃度が服用前(0日目)と比較して高く現れた。「黒豆、蒲公英、及び金銀花」の3種の抽出物を含む錠剤(第7の棒群)の場合にも、錠剤服用日と比較して服用後3日目となる日のコチニン濃度が比較的高く現れ、このような様相は、1種の生薬抽出物だけを含む錠剤(第1乃至第3の棒群)または2種の生薬抽出物だけを含む錠剤(第4乃至第6の棒群)を服用した場合と比較して、顕著な差異を示すものである。   As can be seen from the graph, when taking tablets containing all 6 kinds of herbal extracts (11th bar group), it is the third day after taking compared to before taking (day 0). The urinary cotinine concentration was the highest. Next, in the case of taking a tablet further containing one kind of herbal extract in addition to “Black Bean, Koei Hou, Gold and Silver Flower” (8th, 9th, 10th bar group) The cotinine concentration on one day appeared higher than before taking (day 0). In the case of tablets (seventh group of rods) containing three kinds of extracts of “Black Bean, Koei Sasa, and Gold and Silver Flowers”, the cotinine concentration on the third day after taking the tablet is compared with the day of taking the tablet. Such an aspect appears as a tablet containing only one herbal extract (first to third bars) or a tablet containing only two herbal extracts (fourth to sixth bars). ) Is markedly different from the case of taking).

図2に示されていない他の1種の生薬抽出物だけを含む錠剤、または2種、または「黒豆、蒲公英、及び金銀花」を必須的に含まない3種以上の生薬抽出物を含む錠剤に対しても実験したが、これらは、前記図面に示したものに比べて低い解毒効果を示し、図示を省略した。   Tablets containing only one other herbal extract not shown in FIG. 2, or two or three or more herbal extracts that essentially do not contain “Kurome, Koei, and Gold and Silver Flowers” Although these were also tested, they showed a lower detoxification effect than those shown in the drawings, and the illustration was omitted.

このような結果から、本発明による6種の生薬抽出物を全て含む組成物が人体内でのニコチンの解毒効果が最も良く、少なくとも「黒豆、蒲公英、及び金銀花」を含む3種以上の生薬抽出物の混合物が単独または2種または3種以上のその他の生薬抽出物の混合物に比べて有意な人体内ニコチン解毒効果を有することを発見した。   From these results, the composition containing all the six kinds of herbal extracts according to the present invention has the best detoxification effect of nicotine in the human body, and at least three kinds of herbal medicines containing at least “black beans, sung kouei and gold and silver flowers”. It has been discovered that a mixture of extracts has a significant nicotine detoxifying effect in human body compared to a single or a mixture of two or more other herbal extracts.

したがって、以下の実施例では、本発明においてその効果が最も良いものと立証された6種の生薬抽出物を全て含む組成物を使用して、ニコチン急性毒性試験、人体内でのニコチン解毒効果及びダイオキシン解毒効果などを試験した。   Therefore, in the following examples, using a composition containing all six herbal extracts that have been proved to be most effective in the present invention, nicotine acute toxicity test, nicotine detoxification effect in human body and Dioxin detoxification effect was tested.

ニコチン急性毒性試験結果 Nicotine acute toxicity test results

本発明による組成物に対するマウス(mouse)急性毒性試験は、1週間400mg/dayの投与量で本発明による6種の生薬抽出物を全て同量ずつ含む混合粉末Aを飼料と一緒に投与した処理群と、同量の粉末飼料だけを投与した対照群を対象にした。   The mouse acute toxicity test for the composition according to the present invention is a treatment in which a mixed powder A containing the same amount of all six herbal extracts according to the present invention at a dose of 400 mg / day per week is administered together with a feed. The group and the control group administered only the same amount of powdered feed were used as subjects.

予備実験で得られたニコチン致死量である42mg/kgを体重別に調整して、腹腔注射した後、麻痺発生時間、発作開始及び終了時間、そして死亡するまでの所要時間を表1に示した。水溶性であるニコチンは、腹腔内に投与されれば、直ちに体内に吸収される程度に毒性が強くて、神経細胞膜の受容体に反応して、血圧上昇、骨格筋繊維の痙攣誘発、発作による口腔内麻痺などを起こすと知られている(Craig, C. R. and Stizel, R. E. Modern pharmacology 4th ed. Little BROWN. USA. p171-173(1994))。 The nicotine lethal dose obtained in the preliminary experiment, 42 mg / kg, was adjusted according to body weight and injected intraperitoneally. Nicotine, which is water-soluble, is toxic enough to be absorbed into the body immediately when administered intraperitoneally, and in response to nerve cell membrane receptors, it increases blood pressure, induces convulsions of skeletal muscle fibers, and seizures It is known to cause such oral paralysis (Craig, CR and Stizel, RE Modern pharmacology 4 th ed. Little BROWN. USA. p171-173 (1994)).

(表1) ニコチン致死量(42mg/kg)を注射したマウス1)に対する本発明による組成物の保護効果





Figure 0004100623
(Table 1) Protective effect of the composition according to the present invention on mice injected with lethal dose of nicotine (42 mg / kg) 1)





Figure 0004100623

前記表1から分かるように、ニコチン急性毒性によって初期に発生する麻痺開始時間は、対照群の場合、平均55秒、本発明による混合粉末Aを投与した処理群は、2分20秒で、本発明による生薬抽出物の摂取が麻痺開始時間を2倍以上遅延させることが明らかになった。 As can be seen from Table 1 above, the onset time of paralysis initially occurring due to acute nicotine toxicity is 55 seconds on average in the control group, and 2 minutes and 20 seconds in the treatment group administered with the mixed powder A according to the present invention. It has been found that the intake of the herbal extract according to the invention delays the onset time of paralysis more than twice.

発作開始及び完了時間においては、対照群の場合、1分26秒から3分39秒まで2分13秒間発作症状を示したが、本発明による混合粉末投与群の場合、3分13秒から4分23秒まで1分10秒間発作症状を示した。また、麻痺開始時間から発作開始までの所要時間は、対照群の場合、31秒、本発明による生薬抽出物の混合粉末処理群は、53秒で、対照群に比べて延びることが分かった。   In terms of seizure onset and completion time, the control group showed seizure symptoms from 1 minute 26 seconds to 3 minutes 39 seconds for 2 minutes 13 seconds, whereas the mixed powder administration group according to the present invention exhibited 3 minutes 13 seconds to 4 minutes. Seizures were exhibited for 1 minute and 10 seconds up to 23 minutes. The time required from the start of paralysis to the start of seizure was 31 seconds for the control group, and 53 seconds for the mixed powder treatment group of the herbal extract according to the present invention, which was longer than the control group.

そして、対照群の場合、11匹のうち9匹が発作が停止した後、平均4分6秒間コマ(coma)状態にあってから死亡することになり、致死量のニコチン注射後7分45秒ぶりに死亡することが確認され、2匹は回復した。これに対し、本発明による混合粉末A投与群は、11匹のうち3匹が発作停止後1分ぶりに死亡したが、残りの8匹は回復した。   In the case of the control group, 9 out of 11 animals died after the seizure had stopped and were in coma for an average of 4 minutes and 6 seconds, and 7 minutes and 45 seconds after the injection of a lethal dose of nicotine. Two animals were confirmed to die for the first time and two recovered. In contrast, in the mixed powder A administration group according to the present invention, 3 out of 11 animals died for the first time after the seizure stopped, but the remaining 8 recovered.

このように、本発明による生薬抽出物の混合粉末を給餌したマウスは、致死量のニコチンを注射した急性毒性実験で対照群に比べて麻痺発生及び発作開始時間の遅延、発作持続時間の短縮、及びニコチン致死量注射による生存率が18%から73%に増加することが確認された。   Thus, mice fed the mixed powder of the herbal extract according to the present invention, in the acute toxicity experiment injected with a lethal dose of nicotine, the occurrence of paralysis and the delay in seizure start time, shortening the seizure duration compared to the control group, It was also confirmed that the survival rate from nicotine lethal dose injection increased from 18% to 73%.

このような結果は、前記生薬のうち金銀花をはじめとする他の生薬抽出物に含まれたイリドイドグルコシド(iridoid glucosides)と多価フェノール性の化合物(polyphenolic compounds)が、ニコチンがコチニンに分解されるのを促進させることによって、骨格筋繊維の痙攣、発作などにより誘発される麻痺症状を緩和させ、ニコチンによる死亡率を大きく減少させると考えられる。   These results show that iridoid glucosides and polyphenolic compounds contained in other herbal extracts such as gold and silver flowers in the herbal medicine are decomposed into nicotine into cotinine. It is considered that the paralysis symptom induced by convulsions, seizures, etc. of skeletal muscle fibers is alleviated and mortality due to nicotine is greatly reduced.

人体内でのニコチン解毒試験 Nicotine detoxification test in human body

本発明による組成物(混合粉末A)に対するニコチン分解効能を検定するために、標準コチニン(standard cotinine)で検量線を作成し、下記の数1のような直線方程式を得た。   In order to test the efficacy of nicotine degradation for the composition according to the present invention (mixed powder A), a calibration curve was prepared using standard cotinine, and a linear equation such as the following Equation 1 was obtained.

(数1)
y=0.0009x+0.1344(R=0.992) ....(1)
(Equation 1)
y = 0.0009x + 1.344 (R 2 = 0.992). . . . (1)

上記式1で、xは、検体の吸光度であり、yは、吸光度によるコチニン量であり、Rは、二乗値が1に近いほど、正確度が高いことを意味する。   In the above formula 1, x is the absorbance of the specimen, y is the amount of cotinine due to the absorbance, and R means that the closer the square value is to 1, the higher the accuracy.

被試験者の尿からコチニンを定量し、尿に含まれて排出されるコチニンの性向を図3に示した。なお、図3は、実施例1で生薬抽出物間の効果を比較するために実験したデータである棒グラフのうち第11の棒群だけを分離して単独で示したものである。   Cotinine was quantified from the urine of the test subject, and the propensity of cotinin to be excreted in the urine is shown in FIG. In addition, FIG. 3 isolate | separates and shows only the 11th bar | burr group among the bar graphs which are the data experimented in order to compare the effect between crude drug extracts in Example 1. FIG.

図3に示すように、被試験者が本発明による6種の生薬抽出物の混合粉末で製造された錠剤を服用する前に採取した0日目試料では、平均197.4±4.9uMと高いコチニン排泄様相を示し、摂取後3日目には、302.9±50.4uMと排泄量が急激に増加する傾向を示した。7日目には、コチニン排泄量が急激に減少して、27.6±8.5uMであり、14日目には若干上昇し、21日後からは10uM以下とだんだん安定した排出性向を示すことが分かった。   As shown in FIG. 3, the average value of 197.4 ± 4.9 uM was obtained on the day 0 sample taken before the subject took tablets made of the mixed powder of 6 kinds of herbal extracts according to the present invention. A high cotinine excretion pattern was shown, and on the third day after ingestion, the excretion amount increased rapidly to 302.9 ± 50.4 uM. On the 7th day, the amount of cotinine excretion decreases sharply to 27.6 ± 8.5uM, rises slightly on the 14th day, and shows a stable discharge tendency to 10uM or less after 21 days. I understood.

Kyungなどの報告(Kyung, Y. J. and Lee, D. H. Enhanced conversion to cotinine from nicotine by green tea extract. Korean J. Environmental Agriculture. 19: 147-153(2000))によれば、in vitroで緑茶抽出物によるニコチンの分解促進結果、コチニン生成率が顕著に増加して、緑茶抽出物がニコチン分解を促進する可能性があることを確認した。また、緑茶及び桑葉、銀杏、陳皮、甘草、林檎、レモン抽出物混合製剤に対するニコチン分解臨床実験では、30分間隔で3回採取した尿において、水だけを飲用した対照群より前記抽出物混合製剤を飲用した投与群の場合、コチニン排出量が平均20uMさらに排出され、前記抽出物混合製剤が体内でニコチンをコチニンに分解する促進剤として作用したり、ニコチンがニトロソアミン(nitrosamine)類に転換されるのを抑制して、相対的にコチニンに変換される量が増加するからであると言われている(Kim, J. H., Lee, D. H., Cho, H. J. and Jeong, J. M. Effects of phyto-extract mixture on the nicotine decomposition. J. Fd Hyg. Safety. 17: 8-14(2002))。   According to a report by Kyung et al. (Kyung, YJ and Lee, DH Enhanced conversion to cotinine from nicotine by green tea extract. Korean J. Environmental Agriculture. 19: 147-153 (2000)), nicotine with green tea extract in vitro. As a result of promoting the degradation of, the production rate of cotinine was remarkably increased, and it was confirmed that the green tea extract might promote the degradation of nicotine. In addition, in a nicotine degradation clinical experiment for green tea and mulberry leaves, ginkgo, cinnamon, licorice, apple and lemon extract mixed preparation, the extract was mixed with the urine collected three times at 30-minute intervals from the control group drinking only water. In the case of the administration group in which the preparation was drunk, the average amount of cotinine excretion was further eliminated by 20 uM, and the extract preparation acted as an accelerator for decomposing nicotine into cotinine in the body, or nicotine was converted to nitrosamines. It is said that the amount converted to cotinine is relatively increased (Kim, JH, Lee, DH, Cho, HJ and Jeong, JM Effects of phyto-extract mixture on the nicotine decomposition. J. Fd Hyg. Safety. 17: 8-14 (2002)).

本実験結果、本発明による6種の生薬抽出物の混合粉末錠剤服用後1週間は、喫煙により一定水準以上に維持された血中ニコチンの分解が促進され、尿中のコチニン排泄量が増加し、1週間経過後からは、蓄積された血中ニコチン濃度の低下により尿中のコチニン含量が前記生薬抽出物の混合粉末錠剤服用前に比べて5%以下の水準に減少し、強力なニコチン排出及び解毒力を確認することができた。   As a result of this experiment, the degradation of blood nicotine maintained above a certain level by smoking was promoted for one week after taking the mixed powder tablets of the six kinds of herbal extracts according to the present invention, and the amount of cotinine excretion in urine increased. After one week, the urinary cotinine content decreased to a level of 5% or less compared to before taking the mixed powder tablet of the herbal extract due to a decrease in the accumulated blood nicotine concentration, and powerful nicotine excretion And the detoxification power could be confirmed.

ダイオキシン(TCDD)急性毒性試験 Dioxin (TCDD) acute toxicity test

(1)本発明による組成物のTCDDに露出されたラット血液の臨床及び化学的指数に及ぼす影響   (1) Effect of the composition according to the invention on clinical and chemical indices of rat blood exposed to TCDD

本発明による組成物(混合粉末A)の給餌がTCDDで急性毒性を誘導したラット血液の臨床及び化学的指数に及ぼす影響を試験した結果が表2に示されている。   The results of testing the effect of feeding the composition according to the invention (mixed powder A) on the clinical and chemical index of rat blood induced acute toxicity with TCDD are shown in Table 2.

(表2) TCDDに露出された雄ラットの血液の臨床化学的指数に及ぼす本発明による組成物の効果

Figure 0004100623
Table 2 Effect of the composition according to the invention on the clinical chemistry index of blood of male rats exposed to TCDD
Figure 0004100623

前記表2から分かるように、白血球数の場合、生理食塩水だけを投与した第1の群に比べてTCDDを投与した第3の群では、46%減少し、第4の群及び第5の群でも減少した(p<0.05)。赤血球数の場合、第1の群と比較して、TCDDを投与した全ての群で有意差はないが、若干の減少現象が現れ、TCDD急性毒性を誘発したギニーピッグでTCDD投与で赤血球及び白血球数が増加したとの報告とは異なる傾向を示した(Hwang, S. Y., Kim, S. K., Kim S. H., Kwak, Y. S.and Jeong, Y. J. Effect of korean red ginseng on clinical chemical parameters in male guinea pigs exposed acutely to 2,3,7,8-Tetrachlorodibenzo-p-dioxin. J. Korean Soc. Food Sci, Nutr. 28: 1349-1354(1999))。   As can be seen from Table 2, the white blood cell count decreased by 46% in the third group administered with TCDD compared to the first group administered with saline alone, and the fourth and fifth groups. There was also a decrease in the group (p <0.05). In the case of red blood cell count, there was no significant difference in all groups administered TCDD compared with the first group, but a slight decrease phenomenon appeared, and TCDD administration induced TCDD acute toxicity. (Hwang, SY, Kim, SK, Kim SH, Kwak, YSand Jeong, YJ Effect of korean red ginseng on clinical chemical parameters in male guinea pigs exposed acutely to 2, 3,7,8-Tetrachlorodibenzo-p-dioxin. J. Korean Soc. Food Sci, Nutr. 28: 1349-1354 (1999)).

ヘモグロビン濃度の場合、第1の群に比べてTCDD単独投与群(第3の群)の場合、有意差はないが、減少し、本発明による混合粉末Aを前投与した第4の群及び同時投与した第5の群では、ヘモグロビンの減少幅を一部緩和させている。   In the case of the hemoglobin concentration, there was no significant difference in the TCDD single administration group (third group) compared with the first group, but it decreased, and the fourth group and the simultaneous administration of the mixed powder A according to the present invention were reduced. In the administered fifth group, the amount of decrease in hemoglobin is partially alleviated.

血小板の数は、TCDDの投与で減少するが、本発明による混合粉末Aの投与が有意差ありに定常値に近接して回復させる結果を示した(p<0.05)。これは、TCDD急性毒性実験で紅参抽出物の投与(Hwang, S. Y., Kim, S. K., Kim S. H., Kwak, Y. S. and Jeong, Y. J. Effect of korean red ginseng on clinical chemical parameters in male guinea pigs exposed acutely to 2,3,7,8-Tetrachlorodibenzo-p-dioxin. J. Korean Soc. Food Sci, Nutr. 28: 1349-1354(1999))による血小板数の回復現象と類似に現れ、このような結果から見て、TCDD投与は、血小板及び白血球生成障害物質であることが確認できた。   The number of platelets decreased with the administration of TCDD, but the result of the administration of the mixed powder A according to the present invention showed a significant difference and recovered close to the steady value (p <0.05). This is due to the administration of red ginseng extract in TCDD acute toxicity experiments (Hwang, SY, Kim, SK, Kim SH, Kwak, YS and Jeong, YJ Effect of korean red ginseng on clinical chemical parameters in male guinea pigs exposed acutely to 2 , 3,7,8-Tetrachlorodibenzo-p-dioxin. J. Korean Soc. Food Sci, Nutr. 28: 1349-1354 (1999)) TCDD administration was confirmed to be a platelet and leukocyte production disorder substance.

貧血に関連したヘマトクリット(Hematocrit:赤血球容積率)は、第2の群から分かるように、DMSO及びアセトン担体の投与で有意差ありにヘマトクリットを低下させ、TCDDの全ての投与群でも有意差ありに減少した。また、赤血球平均容積(MCV)は、処理群間に有意差がなく、平均赤血球血色素量(MCH)の場合、担体やTCDDを処理した群で一部増加し、平均赤血球血色素濃度(MCHC)は、第1の群に比べて残りの処理群で有意差ありに増加し、担体やTCDDの投与が貧血発生にも影響を与えることが確認され、本発明による混合粉末Aの投与が有意差はないが、MCHC上昇を一部阻止することが明らかになった。   As can be seen from the second group, the hematocrit associated with anemia decreased the hematocrit significantly with the administration of DMSO and acetone carrier, and was significantly different with all TCDD administration groups. Diminished. In addition, the average red blood cell volume (MCV) is not significantly different between the treatment groups, and in the case of the average red blood cell hemoglobin amount (MCH), it partially increases in the group treated with carrier or TCDD, and the average red blood cell hemoglobin concentration (MCHC) is , The remaining treatment group increased significantly with respect to the first group, and it was confirmed that the administration of the carrier and TCDD also affected the occurrence of anemia, and the administration of the mixed powder A according to the present invention showed no significant difference. Although not, it has been shown to partially block MCHC elevation.

その外に、好中球(Neutrophil Segment)(%)及びリンパ球(Lymphocyte)(%)、単核球(Monocyte)(%)は、急慢性炎症、白血病、アレルギー性疾患、造血細胞障害など免疫に関連した血液生化学的指数であって、好中球(%)は、TCDD投与で減少したが、本発明による混合粉末Aの同時投与が有意差ありに担体処理群である第2の群水準に免疫力を回復させることが確認された。リンパ球(%)は、TCDDの全ての投与群で有意差ありに増加することが確認された。単核球(%)は、TCDD投与群である第3の群で減少したが、本発明による混合粉末Aを投与した第4の群及び第5の群で第1群と同様な水準に回復することが分かった。   In addition, Neutrophil Segment (%), Lymphocyte (%), and Monocyte (%) are immune to acute chronic inflammation, leukemia, allergic diseases, hematopoietic cell disorders, etc. The second group in which the neutrophil (%) was decreased by TCDD administration but the simultaneous administration of the mixed powder A according to the present invention was significantly different from the carrier treatment group. It was confirmed that the immunity was restored to the standard. It was confirmed that lymphocytes (%) increased significantly in all administration groups of TCDD. Mononuclear cells (%) decreased in the third group which was the TCDD administration group, but recovered to the same level as the first group in the fourth group and the fifth group to which the mixed powder A according to the present invention was administered. I found out that

(2)本発明による組成物のTCDDに露出されたラットの肝内臨床及び化学的指数に及ぼす影響   (2) Effect of composition according to the present invention on intrahepatic clinical and chemical indices of rats exposed to TCDD

本発明による組成物のTCDDに露出された雄ラットの肝内臨床及び化学的指数に及ぼす影響を表3に示した。   The effect of the composition according to the invention on the intrahepatic clinical and chemical indices of male rats exposed to TCDD is shown in Table 3.

(表3) TCDDに露出された雄ラットの肝内臨床化学的指数に及ぼす本発明による組成物の効果

Figure 0004100623
Table 3 Effect of the composition according to the invention on the intrahepatic clinical chemistry index of male rats exposed to TCDD
Figure 0004100623

前記表3から分かるように、血中蛋白質含量は、全ての試験群で有意差がなく、アルブミン含量は、TCDD投与により有意差(p<0.05)ありに減少したが、本発明による混合粉末Aの投与で対照群である第1群と類似した数値に回復した。また、GOT(グルタミン酸オキサロ酢酸トランスフェラーゼ)活性は、第1の群に比べてTCDD投与時に有意的に増加したが、本発明による混合粉末Aの投与で有意差ありに抑制されることが分かり、GPT(グルタミン酸ピルビン酸トランスフェラーゼ)活性は、TCDD投与で小幅増加したが、本発明による混合粉末Aの投与で活性を低下させることが確認された。アルカリホスファターゼ(Alkaline phosphatase)も、やはりTCDD投与で有意差ありに増加したが、本発明による混合粉末の前投与及び同時投与で第1の群水準に有意差ありに回復した。 As can be seen from Table 3, the blood protein content was not significantly different in all the test groups, and the albumin content was significantly decreased (p <0.05) by TCDD administration. The administration of powder A recovered to a value similar to that in the first group as the control group. In addition, GOT (glutamate oxaloacetate transferase) activity was significantly increased when TCDD was administered as compared to the first group, but was found to be significantly suppressed by administration of mixed powder A according to the present invention. (Glutamate pyruvate transferase) activity was slightly increased by TCDD administration, but it was confirmed that the activity was reduced by administration of mixed powder A according to the present invention. Alkaline phosphatase also increased significantly with TCDD administration, but recovered to the first group level with prior administration and simultaneous administration of the mixed powder according to the present invention.

TCDDに対するマウスの肝毒性試験で、TCDD単独投与群の場合、外観上正常で、TCDD投与後2週間、体重は処理群別に有意差が現れなかったが、剖検時、肝臓は退色して黄褪色になり、肥大し、多くの点状壞死巣が観察された。しかし、本発明による混合粉末A投与群の場合、第1の群に比べて、色相は退色したが、点状壞死巣は、ほとんど存在しないものと観察され、熊胆の併用投与によりTCDDに対する肝の点状壞死巣を顕著に減少させたという結果と類似した(Zhang, H. S., Nam, S. H. and Kang, J. K. Protective Effects of Bear Bile against Hepatotoxicity induced by 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) in Mice. Kor. J. Pharmacogn. 32: 121-127(2001))。   In the hepatotoxicity test of mice against TCDD, in the case of the TCDD single administration group, the appearance was normal and the body weight did not show a significant difference between the treatment groups for 2 weeks after the TCDD administration, but at the time of necropsy, the liver was discolored due to jaundice Became thickened and many punctate moribunds were observed. However, in the case of the mixed powder A administration group according to the present invention, the hue was faded as compared with the first group, but it was observed that there were almost no punctate moribund lesions. (Zhang, HS, Nam, SH and Kang, JK Protective Effects of Bear Bile against Hepatotoxicity induced by 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) in Mice. Kor. J. Pharmacogn. 32: 121-127 (2001)).

また、TCDD急性毒性を誘発したギニーピッグに対する紅参投与結果、アルブミン及び総蛋白質含量の変化がないことが確認され、本実験と差異があり、GOT、GPT、アルカリホスファターゼは、TCDD投与で増加し、紅参の投与で対照群に近く回復させ、肝毒性を軽減させると知られていて、本発明による生薬抽出物の混合物もやはり肝毒性を顕著に軽減させることが確認された(Hwang, S. Y., Kim, S. K., Kim S. H., Kwak, Y. S. and Jeong, Y. J. Effect of korean red ginseng on clinical chemical parameters in male guinea pigs exposed acutely to 2,3,7,8-Tetrachlorodibenzo-p-dioxin. J. Korean Soc. Food Sci, Nutr.28: 1349-1354(1999))。   In addition, as a result of administration of red ginseng to guinea pigs that induced TCDD acute toxicity, it was confirmed that there was no change in albumin and total protein content, which was different from this experiment, and GOT, GPT, alkaline phosphatase increased with TCDD administration, Administration of red ginseng is known to recover close to the control group and reduce liver toxicity, and it was confirmed that the mixture of herbal extracts according to the present invention also significantly reduces liver toxicity (Hwang, SY, Kim, SK, Kim SH, Kwak, YS and Jeong, YJ Effect of korean red ginseng on clinical chemical parameters in male guinea pigs exposed acutely to 2,3,7,8-Tetrachlorodibenzo-p-dioxin.J. Korean Soc. Food Sci, Nutr. 28: 1349-1354 (1999)).

(3)本発明による組成物のTCDDに露出されたラットのすい臓の臨床及び化学的指数に及ぼす影響   (3) Effect of the composition according to the invention on the clinical and chemical index of rat pancreas exposed to TCDD

本発明による組成物のTCDDに露出された雄ラットのすい臓の臨床及び化学的指数に及ぼす影響を表4に示した。   The effect of the composition according to the invention on the clinical and chemical index of male rat pancreas exposed to TCDD is shown in Table 4.

(表4) TCDDに露出された雄ラットのすい臓の臨床化学的指数に及ぼす本発明による組成物の効果

Figure 0004100623
Table 4 Effect of the composition according to the invention on the clinical chemical index of male rat pancreas exposed to TCDD
Figure 0004100623

あらゆる動物において、ダイオキシン、すなわちTCDDの投与は、血中総コレステロール及び中性脂肪の含量を増加させると知られている(Brewster, D. W. and Matsumura, F. 2,3,7,8-Tetrachlorodibenzo-p-dioxin reduces lipoprotein lipase activity in the adipose tissue of the guineapig. Biochem. Biophys. Res. Commun. 122: 810-817(1989))。 In all animals, administration of dioxin, or TCDD, is known to increase the total blood cholesterol and neutral fat content (Brewster, DW and Matsumura, F. 2,3,7,8-Tetrachlorodibenzo-p -dioxin reduces lipoprotein lipase activity in the adipose tissue of the guineapig. Biochem. Biophys. Res. Commun. 122: 810-817 (1989)).

前記表4は、すい臓に対するTCDDの影響を分析したもので、総コレステロール含量は、TCDD投与群全てに有意的に増加し、本発明による混合粉末Aの投与がTCDDによる総コレステロール数値を第1の群水準に回復させなかったが、有意差ありに70%程度回復させることが確認された(p<0.05)。血中中性脂質の場合、担体やTCDD投与で有意差ありに増加することが確認され、本発明による混合粉末Aの投与が、TCDDにより増加する中性脂質を約50%減少させることが確認された。   Table 4 is an analysis of the effect of TCDD on the pancreas. The total cholesterol content is significantly increased in all TCDD administration groups, and the administration of the mixed powder A according to the present invention shows the total cholesterol value by TCDD as the first value. Although it did not recover to the group level, it was confirmed that it recovered about 70% with a significant difference (p <0.05). In the case of blood neutral lipid, it was confirmed that there was a significant difference between the carrier and TCDD administration, and it was confirmed that the administration of the mixed powder A according to the present invention reduced the neutral lipid increased by TCDD by about 50%. It was done.

また、HDLコレステロール(高密度脂蛋白コレステロール)は、TCDD単独投与時に、第1の群に比べて有意差ありに増加したが、本発明による混合粉末Aの前投与及び同時投与で第1の群水準に低下した。このような傾向は、TCDD急性毒性を誘発したギニーピッグの紅参の効果に対する研究と類似した傾向を示すことが分かった(Hwang, S. Y., Kim, S. K., Kim S. H., Kwak, Y. S. and Jeong, Y. J. Effect of korean red ginseng on clinical chemical parameters in male guinea pigs exposed acutely to 2,3,7,8-Tetrachlorodibenzo-p-dioxin. J. Korean Soc. Food Sci, Nutr. 28: 1349-1354(1999))。   HDL cholesterol (high-density lipoprotein cholesterol) increased with TCDD alone with a significant difference compared to the first group. However, the first group of the mixed powder A according to the present invention was pretreated and coadministered. Fell to the level. This trend was found to be similar to the study on the effect of red ginseng on guinea pigs that induced TCDD acute toxicity (Hwang, SY, Kim, SK, Kim SH, Kwak, YS and Jeong, YJ Effect of korean red ginseng on clinical chemical parameters in male guinea pigs exposed acutely to 2,3,7,8-Tetrachlorodibenzo-p-dioxin. J. Korean Soc. Food Sci, Nutr. 28: 1349-1354 (1999)).

その他リパーゼ(lipase)及びアミラーゼ(amlyase)は、処理群間に差異がほとんどないものと確認された。   Other lipases and amylases were confirmed to have little difference between treatment groups.

(4)本発明による組成物のTCDDに露出されたラットの腎臓の臨床及び化学的指数に及ぼす影響   (4) Effect of the composition according to the invention on the clinical and chemical index of rat kidneys exposed to TCDD.

本発明による組成物のTCDDに露出された雄ラットの腎臓の臨床及び化学的指数に及ぼす影響を表5に示した。 The effect of the composition according to the invention on the clinical and chemical indices of male rat kidneys exposed to TCDD is shown in Table 5.

(表5) TCDDに露出された雄ラットの腎臓の臨床化学的指数に及ぼす本発明による組成物の効果

Figure 0004100623
Table 5 Effect of the composition according to the invention on the clinical chemistry index of male rat kidneys exposed to TCDD
Figure 0004100623

前記表5から分かるように、TCDD投与による腎臓関連血液学的指数は、血中尿素態窒素(blood urea nitrogen)は、全ての処理群でほとんど差異がなく、クレアチニン(creatinine)の場合、TCDDだけを投与した第3の群において0.53±0.23と第1の群に比べて有意差ありに増加したが、本発明による混合粉末A投与群である第4の群及び第5の群の場合、担体投与群(第2の群)と同じ数値を示し、TCDDによる増加を抑制することが確認された。尿酸(Uric acid)の濃度は、処理群間に有意差はないが、担体及びTCDD投与群で増加し、本発明による混合粉末Aの投与で減少する傾向を示した。   As can be seen from Table 5 above, the kidney-related hematological index by TCDD administration shows that blood urea nitrogen has almost no difference in all treatment groups, and in the case of creatinine, only TCDD In the third group to which shampoo was administered, 0.53 ± 0.23 increased significantly compared to the first group, but the fourth and fifth groups which were the mixed powder A administration group according to the present invention In this case, the same numerical value as in the carrier-administered group (second group) was shown, and it was confirmed that the increase due to TCDD was suppressed. The concentration of uric acid (Uric acid) was not significantly different between the treatment groups, but increased in the carrier and TCDD administration groups, and showed a tendency to decrease with the administration of the mixed powder A according to the present invention.

そして、カルシウム(Ca)及び燐酸(P)の含量には、処理群別に変化がないが、血中鉄分(Fe)含量は、TCDD投与で有意差ありに減少したが、本発明による混合粉末Aの前投与(第4の群)及び同時投与(第5の群)が正常水準以上に完全に回復させることが分かった。   And although the content of calcium (Ca) and phosphoric acid (P) is not changed between treatment groups, the iron (Fe) content in blood decreased with TCDD administration with a significant difference. It was found that pre-administration (fourth group) and simultaneous administration (fifth group) completely recovered above normal levels.

腎臓は、老廃物排泄及び体液調節による恒常性維持、そしてホルモン関連内分泌機能を担当していて、血流量が多く、老廃物をろ過させる過程で血液に含有された毒性物質に露出される機会が高く、一時的に保存される間、毒性物質の濃縮が起きて毒性物質の標的になる(Hwang, S. Y., Yang, J. B., Chang, C. S., Lee, Y. C. and Lee, H. Y. Protective effect of cornu parvum extract on toxicity induced by 2,3,7,8-tetrachlrodibenzo-p-dioxin in rat.Korea J Oreintal Physiology & Pathology. 16: 647-679(2002))。このような結果から見て、腎臓は、脂肪組織に囲まれているため、脂肪組織に沈着されるTCDDによる損傷に起因してこのような結果が現れたものと判断される。 The kidneys are responsible for waste excretion, maintaining homeostasis by regulating body fluids, and hormone-related endocrine functions.The kidneys have a high blood flow and are exposed to toxic substances contained in the blood in the process of filtering waste products. During high and temporary storage, the concentration of toxic substances occurs and becomes the target of toxic substances (Hwang, SY, Yang, JB, Chang, CS, Lee, YC and Lee, HY Protective effect of cornu parvum extract on toxicity induced by 2,3,7,8-tetrachlrodibenzo-p-dioxin in rat. Korea J Oreintal Physiology & Pathology. 16: 647-679 (2002)). From such a result, it is determined that such a result appears due to damage caused by TCDD deposited in the adipose tissue because the kidney is surrounded by adipose tissue.

(5)本発明による組成物のTCDDに露出されたラットの心臓の臨床及び化学的指数に及ぼす影響   (5) Effect of the composition according to the invention on the clinical and chemical indices of rat hearts exposed to TCDD.

本発明による組成物のTCDDに露出された雄ラットの心臓の臨床及び化学的指数に及ぼす影響を表6に示した。   The effect of the composition according to the invention on the clinical and chemical indices of the heart of male rats exposed to TCDD is shown in Table 6.

(表6) TCDDに露出された雄ラットの心臓の臨床化学的指数に及ぼす本発明による組成物の効果

Figure 0004100623
Table 6 Effect of the composition according to the invention on the clinical chemical index of the heart of male rats exposed to TCDD
Figure 0004100623

心臓と関連した血液化学的指数では、表6から分かるように、肝疾患及び心筋、骨格筋の疲労度などを判別する数値である乳酸脱水素酵素(lactate dehydrogenase)の場合、TCDDの投与がほとんど影響を及ぼさなかったが、本発明による混合粉末Aの前投与(第4の群)及び同時投与(第5の群)時に、対照群(第1の群)よりも低い数値を示し、筋肉疲労度減少及び持久力増加などに肯定的な影響を及ぼしたものと判断される。 As can be seen from Table 6, in the blood chemistry index related to the heart, in the case of lactate dehydrogenase, which is a numerical value that discriminates the degree of fatigue of liver disease, myocardium, skeletal muscle, etc., TCDD is mostly administered Although it had no effect, the value was lower than that of the control group (first group) at the time of pre-administration (fourth group) and simultaneous administration (fifth group) of the mixed powder A according to the present invention, and muscle fatigue It is judged that it had a positive effect on the decrease in the degree of stamina and the increase in endurance.

クレアチンホスホキナーゼ(Creatine phosphokinase)(CPK)は、ATPの枯渇から形成されたADPを加リン酸分解させることによって、筋収縮の途中に、充分なATP水準を維持できるように調節する酵素であって、TCDDの投与によって正常群に比べて有意差ありに67%減少し、本発明による混合粉末Aの前投与(第4の群)及び同時投与(第5の群)は、影響をほとんど及ぼさないものと確認された。また、筋肉-脳(muscle-brain)においてCPKの数値であるCK-MBも、CPKと同様に、TCDDの投与によって正常群に比べて有意差ありに減少するが、本発明による混合粉末Aの前投与(第4の群)及び同時投与(第5の群)は、ほとんど影響を及ぼさないものと確認された。このようなCPK及びCK-MBの性向は、生体撹乱物質として作用する環境ホルモンであるTCDDが、CPKの活性を撹乱させ、心筋及び他の筋肉に充分なエネルギーを供給しないようにすることで、筋肉の疲労を増加させ、運動性を低下させると考えられる。   Creatine phosphokinase (CPK) is an enzyme that regulates so that sufficient ATP level can be maintained during muscle contraction by phosphorylating ADP formed from depletion of ATP. The TCDD administration significantly decreased 67% compared to the normal group, and the pre-administration (the fourth group) and the co-administration (the fifth group) of the mixed powder A according to the present invention had almost no effect. It was confirmed. In addition, CK-MB, which is the value of CPK in the muscle-brain, is decreased with a significant difference by the administration of TCDD as in CPK, but the mixed powder A according to the present invention is reduced. Pre-administration (fourth group) and simultaneous administration (fifth group) were confirmed to have little effect. The propensity of CPK and CK-MB is to prevent TCDD, an environmental hormone that acts as a biological disruptor, from disrupting the activity of CPK and supplying sufficient energy to the myocardium and other muscles. It is thought to increase muscle fatigue and decrease motility.

このような結果から見て、TCDDが主に代謝される器官が異なり、各器官に現れる毒性が器官によって異なるので、本発明による組成物の毒性軽減作用が組織間に異に現れたものと考えられる。このような様相は、毒性化学物質や薬物の代謝過程が大部分肝でなされ、腎臓、腸管及び皮膚で生ずる反応も薬物解毒及び発癌前駆物質の癌発生過程に重要な役目を担当するとの報告と一致するものと判断される(Vecchini, F., Mace, K., Magdalou, J., Mahe, Y., Bernard B. A. and Shroot, B. Constitutive and inducible expression of drug metabolizing enzymes in cultured human keratinocytes. British J Dermatol. 132: 14-21(1995))。
このように血液の臨床化学指数の変化から見て、TCDD投与は、血液とすい臓に対する毒性作用が、肝臓、腎臓及び心臓に対する作用に比べて一層著しく発現され、本発明による6種の生薬抽出物による毒性軽減作用は、肝臓及びすい臓において著しく発現され、TCDD投与による臨床指数の変化を定常数値に近く回復させることが確認され、本発明による生薬抽出物が体内代謝及び機能障害を一部回復させる物質であることを確認することができた。
From these results, the organs in which TCDD is mainly metabolized are different, and the toxicity that appears in each organ differs depending on the organ. Therefore, it is considered that the toxicity reducing action of the composition according to the present invention appears differently between tissues. It is done. It has been reported that the metabolic processes of toxic chemicals and drugs are mostly carried out in the liver, and reactions that occur in the kidney, intestine and skin play an important role in drug detoxification and carcinogenic processes of carcinogenic precursors. Vecchini, F., Mace, K., Magdalou, J., Mahe, Y., Bernard BA and Shroot, B. Constitutive and inducible expression of drug metabolizing enzymes in cultured human keratinocytes. Dermatol. 132: 14-21 (1995)).
Thus, in view of changes in the clinical chemistry index of blood, TCDD administration exhibits a more markedly toxic effect on blood and pancreas than on liver, kidney and heart, and the six herbal extracts according to the present invention. Toxicity-reducing action by ceramide was remarkably expressed in the liver and pancreas, and it was confirmed that the change in the clinical index by TCDD administration was restored to a steady value. We were able to confirm that it was a substance.

以上説明した実施例では、本発明の組成物に対してニコチン及びダイオキシンの体内毒性軽減効果だけについて主に説明したが、前記毒性物質と関連した他の体内代謝物質または他の身体的疾病と関連しても、本発明の組成物が有意な効果を有することができることは、当業者なら充分に理解することができるだろう。そのような効果は、本発明の範囲に属するものである。   In the embodiments described above, only the effect of nicotine and dioxin on reducing the in vivo toxicity of the composition of the present invention has been mainly described, but it is related to other in-vivo metabolites or other physical diseases related to the toxic substance. Nevertheless, those skilled in the art will appreciate that the compositions of the present invention can have significant effects. Such an effect belongs to the scope of the present invention.

ダイオキシン急性毒性試験のための、本発明による混合粉末Aと2,3,7,8-テトラクロロジベンゾ-p-ダイオキシン(TCDD)の投与に対するプロトコルを示す図である。FIG. 3 shows a protocol for administration of mixed powder A and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) according to the present invention for a dioxin acute toxicity test. 本発明による各生薬抽出物の単独又は混合物を含む錠剤を投与した後、人体内でのニコチン解毒効果を示すグラフである。2 is a graph showing the nicotine detoxification effect in the human body after administration of a tablet containing each herbal extract alone or a mixture according to the present invention. 本発明の一実施例による混合粉末Aで製造された錠剤服用後、尿中のコチニン濃度を示すグラフである。It is a graph which shows the cotinine density | concentration in urine after taking the tablet manufactured with the mixed powder A by one Example of this invention.

Claims (5)

体内ニコチン及びダイオキシンを分解するための、黒豆、蒲公英、金銀花、半夏生、決明子及び甘草の抽出物からなることを特徴とする組成物。 A composition comprising an extract of black beans, koei kan, gold and silver flowers, semi-summer, seiko and licorice for decomposing nicotine and dioxins in the body. 前記各抽出物は、いずれも同一の固形分含量を有するように濃縮されたものを基準にして、1〜20重量部の黒豆抽出物、5〜30重量部の蒲公英抽出物、5〜30重量部の金銀花抽出物、10〜50重量部の半夏生抽出物、5〜30重量部の決明子抽出物及び1〜20重量部の甘草抽出物からなることを特徴とする請求項に記載の組成物。 Each of the extracts is 1 to 20 parts by weight of a black bean extract, 5 to 30 parts by weight of a rice cake, 5 to 30 parts by weight, based on those concentrated to have the same solid content. gold and silver flower extract parts, last seed-sowing day extract 10-50 parts by weight, the composition according to claim 1, characterized by comprising a licorice extract determined Akiko extract and 1-20 parts by weight of 5 to 30 parts by weight object. 経口投与を目的とすることを特徴とする請求項1又は2に記載の組成物。 The composition according to claim 1 or 2 , wherein the composition is intended for oral administration. 各生薬抽出物は、抽出液を濃縮し乾燥させた粉末状態であることを特徴とする請求項1又は2に記載の組成物。 The composition according to claim 1 or 2 , wherein each herbal extract is in a powder state obtained by concentrating and drying the extract. 請求項1又は請求項2に記載の生薬各々を洗浄乾燥した後、細切りして、各生薬重量の10〜30倍のエタノールで各生薬を還流抽出し、抽出された各生薬抽出物を濃縮し凍結乾燥させるか、凍結乾燥させない状態で混合してなることを特徴とする請求項1又は請求項2に記載の組成物の製造方法。 Each of the herbal medicines according to claim 1 or claim 2 is washed and dried, then chopped, and each herbal medicine is refluxed and extracted with 10 to 30 times the weight of each herbal medicine, and each extracted herbal medicine extract is concentrated. 3. The method for producing a composition according to claim 1, wherein the composition is freeze-dried or mixed without being freeze-dried.
JP2003336533A 2003-09-05 2003-09-26 Composition of herbal extract with nicotine and dioxin detoxification Expired - Fee Related JP4100623B2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR10-2003-0062115A KR100526760B1 (en) 2003-09-05 2003-09-05 An oriental herb extracts composition having detoxification effect on the nicotine and dioxin

Publications (2)

Publication Number Publication Date
JP2005082587A JP2005082587A (en) 2005-03-31
JP4100623B2 true JP4100623B2 (en) 2008-06-11

Family

ID=34420512

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003336533A Expired - Fee Related JP4100623B2 (en) 2003-09-05 2003-09-26 Composition of herbal extract with nicotine and dioxin detoxification

Country Status (2)

Country Link
JP (1) JP4100623B2 (en)
KR (1) KR100526760B1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE521512C2 (en) 2001-06-25 2003-11-11 Niconovum Ab Device for administering a substance to the front of an individual's oral cavity
PT1578422E (en) 2002-12-20 2007-06-14 Niconovum Ab PARTICULATE MATERIAL CONTAINING NICOTINE PHYSICALLY AND CHEMICALLY STABLE
AU2007224584A1 (en) 2006-03-16 2007-09-20 Niconovum Ab Improved snuff composition
JP4776474B2 (en) * 2006-08-30 2011-09-21 正喜 服部 Herbal medicine composition
KR100812968B1 (en) * 2006-12-11 2008-03-11 조진원 Herbal herb composition and method for manufacturing the same having an effective effect on removing toxic substances in the human body due to smoking
KR20090025851A (en) * 2007-09-07 2009-03-11 오옥수 Manufacturing method of non-smoking auxiliary beverage and non-smoking auxiliary beverage prepared by the method
CN103933492A (en) * 2013-01-21 2014-07-23 郭继进 Medicine for treating intractable hiccup and preparation method thereof
CN104082291B (en) * 2014-07-02 2016-05-18 谭丕和 A kind of organic plant antidote
JP6444688B2 (en) * 2014-10-16 2018-12-26 フジッコ株式会社 Swelling suppression or improvement agent
CN104524517A (en) * 2014-12-25 2015-04-22 北京资源亚太饲料科技有限公司 Traditional Chinese medicine powder for preventing and treating porcine cumulative toxicosis
KR20160090662A (en) * 2015-01-22 2016-08-01 한국과학기술연구원 Composition for prevention or treatment of retinal diseases comprising small black soybean extract
CN105213975A (en) * 2015-10-19 2016-01-06 青岛市中心医院 A kind of pharmaceutical composition and application thereof for the treatment of liver cirrhosis
CN105311585A (en) * 2015-12-08 2016-02-10 李朝彬 Traditional Chinese medicine composition for treating cirrhosis
CN107996921A (en) * 2016-10-31 2018-05-08 许君寿 honeysuckle beverage
KR101889420B1 (en) * 2016-11-14 2018-09-28 대한민국 Pharmaceutical composition for the prevention and treatment of hepatotoxicity by bisphenol A comprising of a Red ginseng, aururus chinensis (Lour.) Baill, and Cimicifuga heraclerifolia Komarov extracts
CN107320542A (en) * 2017-07-12 2017-11-07 狄振起 Remove Chinese medicine preparation of tongue fur and preparation method thereof
KR102058618B1 (en) * 2018-08-24 2019-12-23 주식회사 성균바이오텍 Composition for prevention or treatment of respiratory diseases induced by particulate matter comprising natural plant extracts

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970000075A (en) * 1995-06-21 1997-01-21 김윤동 Detox tea and its manufacturing method
KR100581216B1 (en) * 1998-12-31 2006-08-18 주식회사 태평양 Blended tea effective to eliminate nocotine with excellent preference
JP3482558B2 (en) * 2000-03-13 2003-12-22 有限会社日中医学研究所 An anti-dioxin health food extracted from fermented soybeans and containing genistein as a main ingredient.
KR100464140B1 (en) * 2001-02-21 2005-01-03 주식회사 리젠 바이오텍 Functional powder for decomposing nicotine and manufacturing method of the same
KR20030010259A (en) * 2001-07-26 2003-02-05 남정춘 Antidotes of crude drugs and fabrication method thereof

Also Published As

Publication number Publication date
KR100526760B1 (en) 2005-11-08
KR20050024884A (en) 2005-03-11
JP2005082587A (en) 2005-03-31

Similar Documents

Publication Publication Date Title
JP4100623B2 (en) Composition of herbal extract with nicotine and dioxin detoxification
KR100360674B1 (en) Herbal composition for preventing and treating dementria
US20090155392A1 (en) Methods and Systems for Sublingual Guarana Administration
NZ532550A (en) Compositions incorporating (-)-hydroxycitric acid, chromium, and gymnemic acid, and related methods for promoting healthy body weight and improving related health factors
Islam et al. Antioxidant and hepatoprotective activity of an ethanol extract of Syzygium jambos (L.) leaves
JP2005325025A (en) Diabetes-preventing/treating composition
US11266668B2 (en) Dietary supplement for glycemia control and diabetes prevention
EP3873235B1 (en) Phyto-therapyc compositions useful to improve the quality of sleep and in the treatment of insonnia, anxiety and depression
US10757961B2 (en) Dietary supplement for glycemia control and diabetes prevention
Zawistowski et al. Garlic grown from air bulbils and its potential health benefits
KR100831621B1 (en) Food composition for lowering blood sugar
WO2019038776A1 (en) A herbal composition for treatment of acidity and indigestion problem
Kadam et al. Anthelmintic activity of Allium sativum.
Hassan Effect of dietary supplementation with tigernut tubers on streptozotocin-induced diabetic rats
JP2008214198A (en) A composition comprising mulberry, lotus, sansa and tandins.
CA2606732C (en) Composition for preventing and treating hangover
KR20050080501A (en) A making method of health assistance food for high blood pressure, fatness, diabetes patients.
Chima et al. The Effect of Ethanol Leaf Extract of Rauwolfia vomitoria on Hepatic Markers of Chloroform Intoxicated Albino Wistar Rats
Chalichem et al. Safety evaluation of LIMAN technology based curcumin formulation through single dose and repeated dose administration in rodents and rabbits
Dhankhar et al. Journal of Pharmaceutical Technology Research and Management
Radheshyam et al. Recent studies on phytomedicine used in diabetic disorder
KR102421081B1 (en) A composition for anti-smoke comprising niacin
Puri Simple Ayurvedic Remedies
Okafor EVALUATION OF HYPOGLYCEMIC ACTIVITY OF ALLIUM SATIVUM VS. ALLIUM CEPA IN EXPERIMENTAL DIABETIC MODELS
Murugavel Preclinical Safety Evaluation of Rasa Karpoora Kuligai

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070605

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20070903

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070912

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071002

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071102

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20071107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20080219

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20080314

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110328

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Ref document number: 4100623

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110328

Year of fee payment: 3

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110328

Year of fee payment: 3

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110328

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110328

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110328

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120328

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120328

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130328

Year of fee payment: 5

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130328

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140328

Year of fee payment: 6

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees